var title_f25_51_26416="Oral aphthae PI";
var content_f25_51_26416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Oral aphthae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shallow ulcers are evident on the buccal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26416=[""].join("\n");
var outline_f25_51_26416=null;
var title_f25_51_26417="Gonococcal ophthalmia neonatorum";
var content_f25_51_26417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gonococcal ophthalmia neonatorum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: The Public Health Image Library, Centers for Disease Control and Prevention. Photo by Dr. J Pledger.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26417=[""].join("\n");
var outline_f25_51_26417=null;
var title_f25_51_26418="Tularemia eschar";
var content_f25_51_26418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tularemia eschar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Todd M. Pollack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26418=[""].join("\n");
var outline_f25_51_26418=null;
var title_f25_51_26419="Erythromycin (ophthalmic): Drug information";
var content_f25_51_26419=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4052?source=see_link\">",
"    see \"Erythromycin (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=see_link\">",
"    see \"Erythromycin (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11426064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilotycin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diomycin&reg;;",
"     </li>",
"     <li>",
"      PMS-Erythromycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8089532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide;",
"     </li>",
"     <li>",
"      Antibiotic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8086401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Conjunctivitis:",
"     </b>",
"     Ophthalmic: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; (1.25 cm) 2-6 times/day depending on the severity of the infection",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8086400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=see_link\">",
"      see \"Erythromycin (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conjunctivitis:",
"     </b>",
"     Children: Ophthalmic: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8086402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8086452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 0.5% (1 g, 3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ilotycin&trade;: 0.5% (1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic [preservative free]: 0.5% (1 g, 3.5 g)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8086453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 0.5% (1 g, 3.5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8086249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8086438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Avoid contact of tip of ophthalmic ointment tube with affected eye",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8086250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of superficial eye infections involving the conjunctiva or cornea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8085308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Erythromycin may be confused with azithromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8086305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Hypersensitivity, minor ocular irritation, redness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8086276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8086277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; For ophthalmic use only. Avoid contamination. Do not touch tip of applicator or let tip of applicator touch eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8086309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Erythromycin (Ophthalmic) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8086251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9792105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Erythromycin has been shown to cross the placenta following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following ophthalmic application is not known. Systemic absorption would be required in order for erythromycin to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9792109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution (AAP considers \"compatible\"); AAP 2001 update pending",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9792108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends that caution be exercised when administering erythromycin ophthalmic ointment to nursing women. Erythromycin has been shown to enter breast milk following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following ophthalmic application is not known. Systemic absorption would be required in order for erythromycin to enter breast milk and reach the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8086455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Erythromycin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/g (3.5 g): $18.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Ilotycin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/g (1 g): $15.34",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ery-V (PH);",
"     </li>",
"     <li>",
"      Oftalmolets (AR);",
"     </li>",
"     <li>",
"      Oftalmolosa Cusi Erythromycin (MY, SG);",
"     </li>",
"     <li>",
"      Optryl (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8089538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26419/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9117 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26419=[""].join("\n");
var outline_f25_51_26419=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426064\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8089532\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086401\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086400\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086402\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086452\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086453\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086249\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086438\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085308\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086305\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086276\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086277\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086309\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086251\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9792105\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9792109\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9792108\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086455\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962016\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8089538\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26420="Gastric prolapse after gastric banding";
var content_f25_51_26420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric prolapse after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) An esophagram showing the appearance of gastric prolapse after gastric banding. This radiograph illustrates the classic appearance of gastric prolapse with stomach overhanging the band.",
"    <br>",
"     (B) Computed tomography (CT) images showing change in the band axis and a large amount of stomach above the band, indicative of gastric prolapse.",
"     <br>",
"      (C) This esophagram demonstrates a gastric prolapse. Note that the axis of the band is from 10 to 4 o'clock. In the normal situation, the band should point to the 2 o'clock and 8 o'clock position.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26420=[""].join("\n");
var outline_f25_51_26420=null;
var title_f25_51_26421="Enoxaparin: Patient drug information";
var content_f25_51_26421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enoxaparin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     see \"Enoxaparin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     see \"Enoxaparin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lovenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enoxaparin Injection;",
"     </li>",
"     <li>",
"      Lovenox&reg;;",
"     </li>",
"     <li>",
"      Lovenox&reg; HP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug in pregnant women who have had a heart valve replaced.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat blood clots.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of heart attacks in patients who have unstable angina or mild heart attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enoxaparin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to pork products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems or low platelet count during past use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you know that you will not take the drug as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and have had a heart valve replaced.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697755",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you weigh less than 100 pounds (45 kilograms).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin on the right or left side of the belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using prefilled syringe, do not get rid of air bubble from syringe before giving.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12419 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26421=[""].join("\n");
var outline_f25_51_26421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165076\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165077\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028837\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028839\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028838\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028843\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028844\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028846\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028841\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028842\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028847\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028848\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=related_link\">",
"      Enoxaparin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=related_link\">",
"      Enoxaparin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26422="Ocular cicatricial pemphigoid pathology PAS";
var content_f25_51_26422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Periodic acid Schiff, 64x. Note the glycogen (purple staining) in the epithelium, but the absence of formed goblet cells.",
"    <br>",
"     (B) Pathology specimen from normal conjunctiva demonstrating the presence of goblet cells.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26422=[""].join("\n");
var outline_f25_51_26422=null;
var title_f25_51_26423="Propafenone: Drug information";
var content_f25_51_26423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propafenone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/19/7478?source=see_link\">",
"    see \"Propafenone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rythmol&reg;;",
"     </li>",
"     <li>",
"      Rythmol&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Propafenone&reg;;",
"     </li>",
"     <li>",
"      Mylan-Propafenone;",
"     </li>",
"     <li>",
"      PMS-Propafenone;",
"     </li>",
"     <li>",
"      Rythmol&reg; Gen-Propafenone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients who exhibit significant widening of QRS complex or second- or third-degree AV block may need dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation (to prevent recurrence):",
"     </b>",
"     Oral:",
"     <i>",
"      Extended release capsule:",
"     </i>",
"     Initial: 225 mg every 12 hours; dosage increase may be made at a minimum of 5-day intervals; may increase to 325 mg every 12 hours; if further increase is necessary, may increase to 425 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular arrhythmias:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Initial: 150 mg every 8 hours; dosage increase may be made at minimum of 3- to 4-day intervals, may increase to 225 mg every 8 hours; if further increase is necessary, may increase to 300 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation, pharmacologic cardioversion (unlabeled use):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     To prevent rapid AV conduction, start an AV nodal-blocking agent (eg, beta-blocker, nondihydropyridine calcium channel blocker) prior to pharmacologic cardioversion. Effect occurs between 2-6 hours after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     600 mg as single dose (Fuster, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13657360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer's labeling; however, 50% of propafenone metabolites (active) are excreted in the urine; use with caution in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F214336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Immediate release tablet: Reduce dose by 70% to 80% in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Extended release capsule: Specific dosage adjustments are not provided in manufacturer's labeling; however, dosage reduction should be considered as drug undergoes hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride: 225 mg, 325 mg, 425 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rythmol&reg; SR: 225 mg, 325 mg, 425 mg [contains soy lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 150 mg, 225 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rythmol&reg;: 150 mg, 225 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F214311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules should be swallowed whole; do not crush or chew; may be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of life-threatening ventricular arrhythmias; treatment of paroxysmal atrial fibrillation/flutter (PAF) or paroxysmal supraventricular tachycardia (PSVT) in patients with disabling symptoms and without structural heart disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsule: Prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F214369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardioversion of recent-onset atrial fibrillation (single dose); supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14116243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: New or worsened arrhythmia (proarrhythmic effect) (2% to 10%), angina (2% to 5%), CHF (1% to 4%), ventricular tachycardia (1% to 3%), palpitation (1% to 3%), AV block (first-degree) (1% to 3%), syncope (1% to 2%), increased QRS interval (1% to 2%), chest pain (1% to 2%), PVCs (1% to 2%), bradycardia (1% to 2%), edema (0% to 1%), bundle branch block (0% to 1%), atrial fibrillation (1%), hypotension (0% to 1%), intraventricular conduction delay (0% to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4% to 15%), fatigue (2% to 6%), headache (2% to 5%), ataxia (0% to 2%), insomnia (0% to 2%), anxiety (1% to 2%), drowsiness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (2% to 11%), unusual taste (3% to 23%), constipation (2% to 7%), dyspepsia (1% to 3%), diarrhea (1% to 3%), xerostomia (1% to 2%), anorexia (1% to 2%), abdominal pain (1% to 2%), flatulence (0% to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (0% to 1%), arthralgia (0% to 1%), weakness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, amnesia, anemia, apnea, AV block (second or third degree), asystole, AV dissociation, cardiac arrest, cholestasis (0.1%), coma, confusion, CHF, depression, granulocytopenia, hepatitis (0.03%), hyperglycemia, impotence, increased bleeding time, leukopenia, lupus erythematosus, mania, memory loss, nephrotic syndrome, paresthesia, peripheral neuropathy, pruritus, psychosis, purpura, renal failure, seizure (0.3%), SIADH, sinus node dysfunction, thrombocytopenia, tinnitus, torsade de pointes, ventricular fibrillation, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F214314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propafenone or any component of the formulation; sinoatrial, AV, and intraventricular disorders of impulse generation and/or conduction (except in patients with a functioning artificial pacemaker); Brugada syndrome, sinus bradycardia; cardiogenic shock; uncompensated cardiac failure; marked hypotension; bronchospastic disorders or severe obstructive pulmonary disease; uncorrected electrolyte abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F214296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agranulocytosis: Agranulocytosis has been reported; generally occurring within the first 2 months of therapy. Upon therapy discontinuation, WBC usually normalized by 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Slows atrioventricular conduction, potentially leading to first degree AV block; degree of PR interval prolongation and increased QRS duration are dose and concentration related. Avoid in patients with conduction disturbances (unless functioning pacemaker present).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Can cause life-threatening drug-induced arrhythmias, including ventricular fibrillation, ventricular tachycardia, asystole, and torsade de pointes (Hii, 1991). The manufacturer notes that propafenone may increase the QT interval; however, due to QRS prolongation; changes in the QT interval are difficult to interpret. In an evaluation of propafenone (450 mg/day) in healthy individuals compared to other selected antiarrhythmic agents, propafenone did not affect repolarization time (eg, QT, QTc, JT, JTc) only depolarization time (ie, QRS interval) (Sarubbi, 1998).  Monitor for proarrhythmic effects, and when necessary, adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Brugada syndrome: Initiation of propafenone may unmask Brugada syndrome; obtain ECG after treatment initiation and discontinue if ECG indicative of Brugada syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Avoid use in patients with HF; similar agents have been shown to increase mortality in this population; may precipitate or exacerbate condition (Lindenfeld, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lupus erythematosus: Positive ANA titers have been reported with use. Titers have decreased with and without therapy discontinuation. Positive titers have not usually been associated with clinical symptoms, although at least one case of drug induced lupus erythematosus has been reported. Consider therapy discontinuation in symptomatic patients with positive ANA titers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary disease: The use of propafenone is not recommended in patients with obstructive lung disease (eg, chronic bronchitis, COPD, emphysema) (Fuster, 2006). Use in patients with bronchospastic disease or severe obstructive lung disease is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 and CYP3A4 inhibitors: Avoid  concurrent use with  CYP2D6 inhibitor and CYP3A4 inhibitor; may result in an increased risk of proarrhythmia or exaggerated beta-adrenergic blocking activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT-prolongation potential: Concurrent use of propafenone with QT-prolonging agents has not been extensively evaluated. The manufacturer recommends withholding Class Ia or Class III antiarrhythmics for at least 5 half-lives prior to starting propafenone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial:",
"     <b>",
"      [U.S. Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.",
"     </b>",
"     An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pacemakers: May alter pacing and sensing thresholds of artificial pacemakers.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class Ia): Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).  Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).  Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Propafenone may increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Propafenone may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): Propafenone may increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Propafenone. Management: Concurrent use of ritonavir-boosted fosamprenavir with propafenone is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with propafenone is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Propafenone may increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Propafenone. Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the arrhythmogenic effect of Propafenone. Saquinavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Propafenone may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: Propafenone may increase the serum concentration of Venlafaxine.  Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/dose increase. Conversely, monitor for decreased venlafaxine levels with profapenone discontinuation/dose decrease.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Propafenone may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F214327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Propafenone serum concentrations may be increased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease propafenone levels. Avoid ephedra (may worsen arrhythmia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women; use only if potential benefit to the mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F214318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Capsule: May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F214316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Propafenone HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (90): $614.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (90): $778.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     425 mg (90): $778.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Rythmol SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (60): $455.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (60): $576.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     425 mg (60): $576.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Propafenone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $163.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (100): $232.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $296.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rythmol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $485.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (100): $638.35",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F214305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, blood pressure, pulse (particularly at initiation of therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F214319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arythmol (GB, IE);",
"     </li>",
"     <li>",
"      Nistaken (MX);",
"     </li>",
"     <li>",
"      Norfenon (MX);",
"     </li>",
"     <li>",
"      Normorytmin (AR);",
"     </li>",
"     <li>",
"      Profex (IL);",
"     </li>",
"     <li>",
"      Pronon (JP);",
"     </li>",
"     <li>",
"      Propafen (CO);",
"     </li>",
"     <li>",
"      Propafenon Genericon (HR);",
"     </li>",
"     <li>",
"      Propafenon Pharmavit (HU);",
"     </li>",
"     <li>",
"      Prorynorm (LU);",
"     </li>",
"     <li>",
"      Rhythmonorm (IN);",
"     </li>",
"     <li>",
"      Ritmocor (CN);",
"     </li>",
"     <li>",
"      Ritmonorm (BR, PY);",
"     </li>",
"     <li>",
"      Rythmex (IL);",
"     </li>",
"     <li>",
"      Rythmol (CO, FR, ZA);",
"     </li>",
"     <li>",
"      Rythmonorm (GR);",
"     </li>",
"     <li>",
"      Rytmocard (BG, PH);",
"     </li>",
"     <li>",
"      Rytmonorm (BE, CH, CL, CZ, DE, DK, EE, ES, FI, HK, HN, HR, HU, ID, IT, JO, KP, LU, MY, NL, NZ, PE, PL, PT, RU, SE, SG, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Rytmonorma (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F214295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propafenone is a class 1c antiarrhythmic agent which possesses local anesthetic properties, blocks the fast inward sodium current, and slows the rate of increase of the action potential. Prolongs conduction and refractoriness in all areas of the myocardium, with a slightly more pronounced effect on intraventricular conduction; it prolongs effective refractory period, reduces spontaneous automaticity and exhibits some beta-blockade activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 252 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95% to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2D6, CYP3A4 and CYP1A2 to two active metabolites (5-hydroxypropafenone and N-depropylpropafenone) then ultimately to glucuronide or sulfate conjugates. Two genetically determined metabolism groups exist (extensive and poor metabolizers); 10% of Caucasians are poor metabolizers. Exhibits nonlinear pharmacokinetics; when dose is increased from 300-900 mg/day, serum concentrations increase tenfold; this nonlinearity is thought to be due to saturable first-pass effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release (IR): 150 mg: 3.4%; 300 mg: 10.6%; relative bioavailability of extended release (ER) capsule is less than IR tablet; the bioavailability of  an ER capsule regimen of  325 mg twice-daily regimen approximates an IR tablet regimen of 150 mg 3 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Extensive metabolizers: 2-10 hours; Poor metabolizers: 10-32 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: IR: 3.5 hours; ER: 3-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% unchanged; remainder as glucuronide or sulfate conjugates); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alboni P, Botto GL, Baldi N, et al, \"Outpatient Treatment of Recent-Onset Atrial Fibrillation With the \"Pill-in-the-Pocket\" Approach,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(23):2384-91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Randomized, Placebo-Controlled Trial of Propafenone in the Prophylaxis of Paroxysmal Supraventricular Tachycardia and Paroxysmal Atrial Fibrillation. UK Propafenone PSVT Study Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 92(9):2550-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/7586356/pubmed\" id=\"7586356\" target=\"_blank\">",
"        7586356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boriani G, Capucci A, Lenzi T, et al, &ldquo;Propafenone for Conversion of Recent-Onset Atrial Fibrillation. A Controlled Comparison Between Oral Loading Dose and Intravenous Administration,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1995, 108(2):355-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/7634866/pubmed\" id=\"7634866\" target=\"_blank\">",
"        7634866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boriani G, Biffi M, Capucci A, et al, &ldquo;Oral Propafenone to Convert Recent-Onset Atrial Fibrillation in Patients With and Without Underlying Heart Disease. A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1997, 126(8):621-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/9103129/pubmed\" id=\"9103129\" target=\"_blank\">",
"        9103129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(12):781-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/1900101/pubmed\" id=\"1900101\" target=\"_blank\">",
"        1900101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Funck-Brentano C, Kroemer HK, Lee JT, et al, &ldquo;Propafenone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(8):518-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/2405273/pubmed\" id=\"2405273\" target=\"_blank\">",
"        2405273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hii JT, Wyse DG, Gillis AM, et al, &ldquo;Propafenone-Induced Torsade de Pointes: Cross-Reactivity With Quinidine,&rdquo;",
"      <i>",
"       Pacing Clin Electrophysiol",
"      </i>",
"      , 1991,14(11 Pt 1):1568-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/1721143/pubmed\" id=\"1721143\" target=\"_blank\">",
"        1721143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sarubbi B, Ducceschi V, Briglia N, et al, &ldquo;Compared Effects of Sotalol, Flecainide and Propafenone on Ventricular Repolarization in Patients Free of Underlying Structural Heart Disease,&rdquo;",
"      <i>",
"       Int J Cardiol",
"      </i>",
"      , 1998, 66(2):157-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/9829329/pubmed\" id=\"9829329\" target=\"_blank\">",
"        9829329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siddoway LA, Roden DM, and Woosley RL, &ldquo;Clinical Pharmacology of Propafenone: Pharmacokinetics, Metabolism and Concentration-Response Relations,&rdquo;",
"      <i>",
"       Am J CArdiol",
"      </i>",
"      , 1984, 54(9):9D-12D.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/6496371/pubmed\" id=\"6496371\" target=\"_blank\">",
"        6496371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/51/26423/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9821 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26423=[""].join("\n");
var outline_f25_51_26423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709354\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214329\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214330\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214373\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214334\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214335\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657360\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214336\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214307\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214292\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214311\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214310\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214369\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14116243\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214371\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214314\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214296\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214366\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214301\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214327\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214303\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214317\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214339\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214318\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214316\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214305\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214319\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214295\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214313\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/19/7478?source=related_link\">",
"      Propafenone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26424="Arterial catheterization techniques for invasive monitoring";
var content_f25_51_26424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arterial catheterization techniques for invasive monitoring",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Gilles Clermont, MDCM, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Arthur C Theodore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26424/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26424/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/51/26424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial catheters (also called intra-arterial catheters or A-lines) are common in critically ill patients. They can be used to obtain arterial blood for laboratory testing, and for direct measurement of blood pressure and cardiac output. However, insertion of an arterial catheter is an invasive procedure and complications can occur.",
"   </p>",
"   <p>",
"    This topic will review the indications, insertion techniques, and complications of arterial catheterization. The use of arterial catheters to monitor blood pressure is also reviewed. Percutaneous arterial puncture and arterial blood gases (ABGs) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of an indwelling arterial catheter include continuous access to arterial blood and the ability to continuously measure the blood pressure. As a result, arterial catheterization is indicated when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent blood gases are necessary, such as with acute respiratory failure.",
"     </li>",
"     <li>",
"      The blood pressure must be monitored closely, such as during shock, major surgery, hypertensive emergency, or vasopressor therapy. This is particularly true if the blood pressure abnormality is acute or the blood pressure is labile.",
"     </li>",
"     <li>",
"      Continuous monitoring of cardiac output and stroke volume are needed but it is impractical to place a pulmonary artery catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who do not have central venous access, arterial catheters can be used in lieu of venipuncture to obtain blood specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSERTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The required equipment for arterial cannulation is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78590 \" href=\"UTD.htm?25/7/25723\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial catheters are placed under sterile conditions. The access site is prepared and draped with standard techniques. Full barrier precautions (including eye protection) should be used to minimize the risk of disease transmission associated with blood splatter, and reduce the potential for catheter site infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial step in arterial catheterization is locating a palpable arterial pulse. Data do not support a particular site, but common sites include the radial, femoral, brachial, dorsalis pedis, or axillary arteries. In the pediatric population, the temporal and umbilical arteries can also be used. These sites are the same as those used for percutaneous needle puncture and anatomy landmarks are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H4#H4\">",
"     \"Arterial blood gases\", section on 'Site selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients undergoing radial or dorsalis pedis arterial catheterization should have the collateral flow to the hand or foot assessed prior to the procedure to identify increased risk for an ischemic complication. Collateral flow to the radial artery can be evaluated by the Allen test or modified Allen test. The Allen test and modified Allen test are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H4#H4\">",
"     \"Arterial blood gases\", section on 'Site selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collateral flow to the dorsalis pedis artery can be evaluated in a similar manner by occluding the dorsalis pedis artery and compressing the nail bed of the great toe. Color should return rapidly to the nail bed when pressure on the toenail is released.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ultrasound guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest using ultrasound to identify and guide catheter placement for patients in whom vessel palpation is difficult (eg, small vessels, obesity). Either B-mode or color duplex imaging can be used to identify the vessel, although visualization of needle placement is better with B-mode imaging due to less artifact. An echogenic needle system improves visualization under ultrasound guidance.",
"   </p>",
"   <p>",
"    The use of ultrasound was first described for arterial site salvage following failure of traditional methods; however, ultrasound is used more and more for initial arterial catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. A metaanalysis of four trials (adults and children) that included 152 patients undergoing arterial line placement guided by palpation and 159 with ultrasound-guided access found significant improvement in the rate of successful first attempt for the ultrasound-guided group compared with palpation (relative risk, 1.71; 95% CI 1.25-2.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/6\">",
"     6",
"    </a>",
"    ]. The benefit of ultrasound is the real-time visualization of the needle entering the vessel. When used only for mapping the vessel, no benefit is seen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a palpable arterial pulse has been identified, the planned catheterization site is sterilely prepped. For the radial artery, the wrist is immobilized on a padded armboard. Local analgesia should be considered because it appears to prevent pain without adversely impacting the success of the procedure in patients undergoing percutaneous needle puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A skin nick (ie, dermatotomy) should be considered in patients with tough skin to prevent a skin plug from occluding the insertion needle and damage to the plastic component of the catheter. If a dermatotomy is performed, local analgesia is mandatory.",
"   </p>",
"   <p>",
"    Catheter insertion can be performed using one of three different approaches: the separate-guidewire approach, the integral-guidewire approach, or the direct puncture approach. The catheter should be secured after its insertion, usually with one or two sutures or alternatively with a sutureless fixation device.",
"   </p>",
"   <p>",
"    We suggest either guidewire approach, unless the operator has experience with and is more comfortable with the direct puncture approach. In addition, we advocate changing to a guidewire approach if difficulties are encountered with the direct puncture approach. In one trial, 69 critically ill patients were randomly assigned to have arterial catheters placed by the direct puncture, separate-guidewire, or integral-guidewire approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/10\">",
"     10",
"    </a>",
"    ]. The direct puncture approach was less likely to be successful, took longer to perform, used more catheters, and required more punctures than the separate-guidewire or integral-guidewire approaches. Similarly, in a prospective cohort study of 138 patients, insertion was more often successful using a guidewire approach, rather than the direct puncture approach (82 versus 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/11\">",
"     11",
"    </a>",
"    ]. In this study, greater success was achieved in male patients and those with a bounding arterial pulse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Separate-guidewire",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the separate-guidewire approach, the nondominant hand gently palpates the artery, while the dominant hand manipulates the intravascular catheter (an outer catheter over a needle) (",
"    <a class=\"graphic graphic_figure graphicRef74903 \" href=\"UTD.htm?14/17/14616\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The intravascular catheter is inserted at a 30 to 45 degree angle and advanced slowly until pulsatile blood return is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/12\">",
"     12",
"    </a>",
"    ]. Once pulsatile blood return is observed, the intravascular catheter is advanced slightly, until the blood return ceases. This step acknowledges that initial blood return begins as soon as the needle enters the lumen, but before the outer catheter also enters the artery's lumen. Advancing the intravascular catheter ensures that the outer catheter has advanced into the lumen.",
"   </p>",
"   <p>",
"    The nondominant hand then stabilizes the intravascular catheter while the dominant hand removes the needle from the intravascular catheter.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pulsatile blood return is observed after the needle is removed, a guidewire is advanced through the outer catheter.",
"     </li>",
"     <li>",
"      If pulsatile blood is not observed after the needle is removed, the outer catheter is gently withdrawn until pulsatile blood return is obtained. A guidewire is then advanced through the outer catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidewire is advanced until its distal end is well beyond the distal end of the outer catheter. Finally, the outer catheter is advanced into the artery over the guidewire and the guidewire is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Integral-guidewire",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integral-guidewire approach is similar, except the guidewire is inseparable from the intravascular catheter (",
"    <a class=\"graphic graphic_figure graphicRef74903 \" href=\"UTD.htm?14/17/14616\">",
"     figure 1",
"    </a>",
"    ). The nondominant hand gently palpates the artery, while the dominant hand manipulates the needle-guidewire-catheter unit. The needle-guidewire-catheter unit is inserted at a 30 to 45 degree angle and advanced slowly until pulsatile blood return is obtained. The nondominant hand then stabilizes the unit, while the dominant hand advances the guidewire tab to push the wire into and through the needle and catheter. The catheter is advanced into the artery over the needle and guidewire. Finally, the needle-guidewire unit is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Direct puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the direct puncture approach, the nondominant hand gently palpates the artery, while the dominant hand manipulates the intravascular",
"    <span class=\"nowrap\">",
"     needle/catheter.",
"    </span>",
"    The intravascular",
"    <span class=\"nowrap\">",
"     needle/catheter",
"    </span>",
"    is inserted at a 30 to 45 degree angle and advanced slowly until pulsatile blood return is obtained. The outer catheter is then advanced into the artery directly from the needle without the aid of a guidewire.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant complications of arterial catheterization are uncommon. Most complications can occur at any insertion site, although a few site-specific complications exist (",
"    <a class=\"graphic graphic_table graphicRef63291 \" href=\"UTD.htm?32/55/33659\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     All sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of indwelling arterial catheters include local and systemic infection, bleeding, hematoma, bruising, pain, swelling, and iatrogenic blood loss. In addition, vascular complications can occur, such as blood vessel injury, thromboembolism, vasospasm, pseudoaneurysm, and arteriovenous fistula. Several of the vascular complications can cause distal ischemia or, if severe, necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis can be detected by Doppler ultrasound in up to 25 percent of patients who have an arterial catheter, although clinically significant thrombosis occurs in less than 1 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Risk factors for thrombosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased duration of catheterization (ie, &gt;72 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/15,17\">",
"       15,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Larger catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Smaller blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low flow states (eg, low cardiac output)",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Vasospastic disorders (eg, Raynaud phenomenon) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous controlled trials have demonstrated the incidence of thrombosis can be reduced by flushing the arterial catheter with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , rather than normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. This is best illustrated by a trial that randomly assigned 5139 patients to receive either a heparinized or non-heparinized flush for up to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/22\">",
"     22",
"    </a>",
"    ]. Heparin increased the patency of the arterial catheters, as determined by evaluation of the backflow of arterial blood and the waveform achieved with the catheter.",
"   </p>",
"   <p>",
"    Sodium citrate is an alternative flushing agent with catheter patency rates equivalent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and, therefore, may be useful when heparin is contraindicated (ie, heparin-induced thrombocytopenia). A trial randomly assigned 40 critically ill patients to receive 1.4 % sodium citrate flush solution, or heparin flush solution for up to 96 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/23\">",
"     23",
"    </a>",
"    ]. There were no differences in arterial catheter patency assessed at 48 and 96 hours. However, these results should be applied with caution because of the small size of this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremity ischemia as a consequence of embolization is due to dislodgement of thrombus or atheromatous debris by the catheter. The nature of symptoms and signs depends upon the presence (or absence) of collateral channels and size of the debris that has embolized. Distal ischemia (ie, in the digits) is more typical of emboli related to indwelling arterial catheters, unless the access site itself thromboses, in which case more proximal limb ischemia will occur. In addition, arterial catheters in proximity to the origin of the carotid artery (eg, axillary artery) can cause cerebral emboli.",
"   </p>",
"   <p>",
"    Distal pulses should be monitored regularly in all patients who have an arterial catheter. Caution is advised during flushing of arterial catheters; high pressure flushing should be avoided to minimize the potential for retrograde embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to estimate the incidence of arterial catheter-related infection because studies used varying definitions and frequently included both arterial and venous catheters. We estimate that 10 to 20 percent of arterial catheters are complicated by local (eg, insertion site) infection, approximately 10 percent by colonization, and 0.4 to 5 percent by bacteremia or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/26-31\">",
"     26-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small studies have not found a relationship between the anatomic site of arterial catheterization and the incidence of arterial catheter-related infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/26,29,32\">",
"     26,29,32",
"    </a>",
"    ]. However, a prospective cohort study that compared femoral with radial arterial catheters in almost 2500 patients found that femoral artery catheters were associated with an increased incidence of both local infection (3.02 versus 0.75 infections per 1000 catheter-days) and bloodstream infection (1.92 versus 0.25 infections per 1000 catheter-days) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/33\">",
"     33",
"    </a>",
"    ]. The average duration of catheter insertion was longer for femoral artery catheters (5.9 versus 5.75 days); however, it is uncertain whether this contributed to the different infection rates since the duration of infected catheters from each site was not reported. No catheters were left in place longer than seven days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several risk factors for arterial catheter-related infection have been identified, including poor aseptic technique during insertion, insertion by surgical cut-down, and increased duration of catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/27,28,30,34\">",
"     27,28,30,34",
"    </a>",
"    ]. Most studies have demonstrated that infection due to arterial catheters is most common among arterial catheters used for four days or longer.",
"   </p>",
"   <p>",
"    There is a paucity of data about prevention of arterial catheter-related infections. Thus, the following approach is extrapolated from studies that evaluated the prevention of catheter-related infection in patients with a central venous catheter or a pulmonary artery catheter (",
"    <a class=\"graphic graphic_table graphicRef65076 \" href=\"UTD.htm?30/48/31499\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial catheters are not routinely changed to a new site [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/31,35\">",
"       31,35",
"      </a>",
"      ]. Instead, we use vigilant clinical assessment of the insertion site and the patient to determine whether an arterial catheter needs to be replaced. One trial randomly assigned 160 critically ill patients with a central venous or pulmonary artery catheter to one of four groups: replacement with a new insertion every three days, replacement by exchange over a guidewire every three days, new insertion when clinically indicated, or replacement by exchange over a guidewire when clinically indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/31\">",
"       31",
"      </a>",
"      ]. There were no differences in the incidence of bloodstream infection among the four groups. New insertions were associated with more mechanical complications.",
"     </li>",
"     <li>",
"      Disposable or reusable transducers are replaced at 96-hour intervals. The associated tubing, continuous flush device, and flush solutions are also replaced. This is based upon studies that evaluated the impact of changing intravenous fluid administration sets in patients with a central venous or pulmonary artery catheter. A meta-analysis of 15 controlled trials found no evidence that changing intravenous fluid administration sets more often than every 96 hours reduced the incidence of bloodstream infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/36\">",
"       36",
"      </a>",
"      ]. The data were insufficient to determine whether changing administration sets less often than every 96 hours affected the incidence of infection.",
"     </li>",
"     <li>",
"      The dressing is replaced when it becomes damp, loose, or soiled, or the arterial catheter is removed or replaced.",
"     </li>",
"     <li>",
"      All catheters placed under emergency conditions (ie, catheters placed without the usual sterile precautions) are replaced as soon as the patient&rsquo;s condition permits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air bubbles in the flush solution of an arterial catheter can embolize antegrade or retrograde and cause ischemic damage to end organs, such as the brain, spinal cord, heart, and skin. In a primate model, 2 mL of air injected into the radial artery with a standard pressurized infusion apparatus could result in clinically significant cerebral air emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/37\">",
"     37",
"    </a>",
"    ]. Such emboli are more likely in smaller patients or those sitting upright. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to realize that air introduced into the arterial circulation via an arterial catheter is more likely to have adverse sequelae than air introduced into the venous circulation via a venous catheter because venous air will travel to the pulmonary capillaries and be filtered out. An exception exists if an anatomic right to left shunt exists. In this situation, venous air can be equally problematic because the pulmonary capillaries can be bypassed with the air traveling directly from the venous to the arterial circulation. Though rare, venous air may not get filtered and may pass through the lung into the arterial circulation even in the absence of a septal defect. This phenomenon has been described as a complication of foam sclerotherapy during the treatment of venous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link&amp;anchor=H28#H28\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\", section on 'Visual and other neurologic disturbances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Iatrogenic blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests not only require withdrawal of the blood sample to be tested, but an additional 3 to 12 mL of blood can be wasted (ie, to avoid sample contamination with saline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ). Substantial blood loss can result if frequent testing is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Strategies to help minimize iatrogenic blood loss include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sampling from the port nearest to the catheter insertion, or using a closed blood draw system that allows re-infusion of unused blood [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of intraarterial blood gas monitoring if withdrawal of blood for ABGs is the major source of blood loss. This technique uses a fluorescent optode to measure arterial pH, PaCO2, and PaO2 measurements as needed without removing blood from the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/42\">",
"       42",
"      </a>",
"      ]. Fiberoptic continuous sensor systems (eg, Paratrend 7+&reg;; Philips Medical Systems) are also available, which may offer an advantage if monitoring is needed over a prolonged period of time [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Site-specific",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each arterial catheterization site is associated with a unique set of potential complications (",
"    <a class=\"graphic graphic_table graphicRef63291 \" href=\"UTD.htm?32/55/33659\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/17,29,44,45\">",
"     17,29,44,45",
"    </a>",
"    ]. As examples, radial artery insertion is associated with peripheral neuropathy, femoral artery insertion with retroperitoneal hematoma, axillary artery insertion with brachial plexopathy, and brachial artery insertion with injury to the median nerve.",
"   </p>",
"   <p>",
"    Although many sites share the same possible complications (eg, bleeding), the frequency of these complications varies among the different insertion sites. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complications associated with radial artery catheterization are occlusion (2 to 35 percent) and hematoma (up to 15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/37,46,47\">",
"       37,46,47",
"      </a>",
"      ]. Permanent injury rarely results from either complication.",
"     </li>",
"     <li>",
"      The most common complication associated with femoral artery catheterization is hematoma (6 percent), which can be large and difficult to detect if extension to the retroperitoneum occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BLOOD PRESSURE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct measurement by an arterial catheter is the gold standard for measuring blood pressure, provided the pressure transducer is free of technical problems. The mean arterial pressure determined by direct measurement generally correlates well with sphygmomanometry in healthy patients. Sphygmomanometry is less accurate in the presence of calcified arteries, shock, cardiac arrhythmias, or increased systemic vascular resistance (eg, vasoconstrictor drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, noninvasive finger artery blood pressure monitoring correlates well with radial artery blood pressure monitoring in ambulatory patients, but should not be relied upon when hemodynamic instability is present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the superiority of direct blood pressure measurement, technical problems may introduce errors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dynamic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dynamic response is determined by two factors, the resonant frequency and the damping coefficient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resonant or natural frequency of the system is the frequency at which it oscillates when stimulated. Physiologic peripheral arterial waveforms have a fundamental frequency of 3 to 5 Hz, although some components may range up to 20 Hz [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/55\">",
"       55",
"      </a>",
"      ]. Thus, the resonant frequency of the system used to monitor arterial pressure must be greater than 20 Hz to avoid ringing and systolic overshoot [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The damping coefficient is a measure of how quickly an oscillating system comes to rest [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/56\">",
"       56",
"      </a>",
"      ]. A system with a high damping coefficient (eg, compliant tubing) absorbs mechanical energy well and causes a diminution in the transmitted waveform.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The damping coefficient and resonant frequency of a monitoring system can be assessed at the bedside by the rapid-flush test (",
"    <a class=\"graphic graphic_figure graphicRef56073 \" href=\"UTD.htm?4/57/5021\">",
"     figure 2",
"    </a>",
"    ). This test is performed by briefly opening and closing the valve in the continuous flush device, which produces a square wave on the monitor. The square wave is followed by ringing (ie, rapid variation around the baseline), and a return to baseline. No ringing is seen with an over-damped system and excessive ringing is seen with an under-damped system. Common causes of underdamping include connecting tubing with stopcocks, excessive tubing length, and patient factors (eg, tachycardia, high output states). A common cause of overdamping is air bubbles in the connecting tubing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Transducer position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transducer position can be checked (ie, zeroed) by turning the stopcock off to the patient and open to air, adjusting the height of the stopcock to align with the level of the heart (usually approximated with the mid-axillary line), and adjusting the monitor to display zero. This procedure should be repeated each time the patient's position is changed, when significant changes in blood pressure are noted, and routinely every six to eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Calibration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine calibration of the monitor and transducer is no longer necessary because the current disposable transducers are standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26424/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial catheterization is indicated when blood pressure must be monitored on a moment-to-moment basis or frequent arterial blood gases (ABGs) are necessary. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct measurement by an arterial catheter is the gold standard for measuring blood pressure. However, errors can be introduced by technical problems, such as an inappropriate dynamic response or faulty transducer position. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Blood pressure monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in arterial catheterization is locating a palpable arterial pulse overlying an accessible and suitable vessel. Common sites include the radial, femoral, brachial, dorsalis pedis, or axillary artery. In the pediatric population, the temporal and umbilical arteries can also be used. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with vessels that are difficult to palpate, we suggest using ultrasound to identify and guide catheter placement (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of ultrasound is associated with fewer attempts, and therefore a quicker time to catheterization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ultrasound guidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to catheterization of the radial or dorsalis pedis artery, we recommend establishing the adequacy of collateral flow to the hand or foot by physical examination, Doppler ultrasound, pulse oximetry or, for the radial artery, the modified Allen test (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that arterial catheters be placed with full barrier precautions (including eye protection) to minimize the risk of disease transmission and reduce the potential for catheter site infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend administering local anesthesia prior to arterial catheterization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Local anesthesia prevents pain without adversely impacting the success of the procedure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most operators, we suggest using the separate-guidewire approach or the integral-guidewire approach, rather than the direct puncture approach (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The catheter should be secured after its insertion, usually with one or two sutures. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not have a contraindication to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (eg, heparin-induced thrombocytopenia), we recommend use of heparinized flush solution over non-heparinized flush solution (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who have a contraindication to heparin, a 1.4% sodium citrate flush solution is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that arterial catheters",
"      <strong>",
"       not",
"      </strong>",
"      be replaced routinely (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Instead, we use vigilant clinical assessment of the insertion site and the patient to determine whether an arterial catheter needs to be replaced. It is preferable not to leave femoral catheters in place for longer than five days and arterial catheters at other sites should not be left in place for more than seven days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that disposable or reusable transducers be replaced at 96-hour intervals (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We replace the associated tubing, continuous flush device, and flush solutions at the same time. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Infection'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Complications of indwelling arterial catheters include local and systemic infection, bleeding, hematoma, bruising, pain, swelling, and iatrogenic blood loss. In addition, vascular complications can occur, such as blood vessel injury, limb ischemia, thromboembolism, vasospasm, pseudoaneurysm, and arteriovenous fistula. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/1\">",
"      McGee WT, Horswell JL, Calderon J, et al. Validation of a continuous, arterial pressure-based cardiac output measurement: a multicenter, prospective clinical trial. Crit Care 2007; 11:R105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/2\">",
"      Maher JJ, Dougherty JM. Radial artery cannulation guided by Doppler ultrasound. Am J Emerg Med 1989; 7:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/3\">",
"      Levin PD, Sheinin O, Gozal Y. Use of ultrasound guidance in the insertion of radial artery catheters. Crit Care Med 2003; 31:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/4\">",
"      Shiver S, Blaivas M, Lyon M. A prospective comparison of ultrasound-guided and blindly placed radial arterial catheters. Acad Emerg Med 2006; 13:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/5\">",
"      Dudeck O, Teichgraeber U, Podrabsky P, et al. A randomized trial assessing the value of ultrasound-guided puncture of the femoral artery for interventional investigations. Int J Cardiovasc Imaging 2004; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/6\">",
"      Shiloh AL, Savel RH, Paulin LM, Eisen LA. Ultrasound-guided catheterization of the radial artery: a systematic review and meta-analysis of randomized controlled trials. Chest 2011; 139:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/7\">",
"      Tada T, Amagasa S, Horikawa H. Absence of efficacy of ultrasonic two-way Doppler flow detector in routine percutaneous arterial cannulation. J Anesth 2003; 17:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/8\">",
"      Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/9\">",
"      Lightowler JV, Elliott MW. Local anaesthetic infiltration prior to arterial puncture for blood gas analysis: a survey of current practice and a randomised double blind placebo controlled trial. J R Coll Physicians Lond 1997; 31:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/10\">",
"      Beards SC, Doedens L, Jackson A, Lipman J. A comparison of arterial lines and insertion techniques in critically ill patients. Anaesthesia 1994; 49:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/11\">",
"      Mangar D, Thrush DN, Connell GR, Downs JB. Direct or modified Seldinger guide wire-directed technique for arterial catheter insertion. Anesth Analg 1993; 76:714.",
"     </a>",
"    </li>",
"    <li>",
"     Tegtmeyer, K, Brady, G, Lai, S, et al. Placement of an arterial line. file://content.nejm.org/cgi/video/354/15/e13 (Accessed on April 17, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/13\">",
"      Weiss BM, Gattiker RI. Complications during and following radial artery cannulation: a prospective study. Intensive Care Med 1986; 12:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/14\">",
"      Davis FM, Stewart JM. Radial artery cannulation. A prospective study in patients undergoing cardiothoracic surgery. Br J Anaesth 1980; 52:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/15\">",
"      Jones RM, Hill AB, Nahrwold ML, Bolles RE. The effect of method of radial artery cannulation on postcannulation blood flow and thrombus formation. Anesthesiology 1981; 55:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/16\">",
"      Bedford RF. Radial arterial function following percutaneous cannulation with 18- and 20-gauge catheters. Anesthesiology 1977; 47:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/17\">",
"      Bedford RF. Long-term radial artery cannulation: effects on subsequent vessel function. Crit Care Med 1978; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/18\">",
"      Zevola DR, Dioso J, Moggio R. Comparison of heparinized and nonheparinized solutions for maintaining patency of arterial and pulmonary artery catheters. Am J Crit Care 1997; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/19\">",
"      Kulkarni M, Elsner C, Ouellet D, Zeldin R. Heparinized saline versus normal saline in maintaining patency of the radial artery catheter. Can J Surg 1994; 37:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/20\">",
"      Clifton GD, Branson P, Kelly HJ, et al. Comparison of normal saline and heparin solutions for maintenance of arterial catheter patency. Heart Lung 1991; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/21\">",
"      Lapum JL. Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature. Can J Cardiovasc Nurs 2006; 16:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/22\">",
"      Evaluation of the effects of heparinized and nonheparinized flush solutions on the patency of arterial pressure monitoring lines: the AACN Thunder Project. By the American Association of Critical-Care Nurses. Am J Crit Care 1993; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/23\">",
"      Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 1993; 103:882.",
"     </a>",
"    </li>",
"    <li>",
"     Czepizak CA, O'Callaghan JM, Venus B, et al. Vascular access. In: Clinical anesthesia practice, Kirby, RR, Gravenstein, N (Eds), W.B. Saunders Company, Philadelphia 1994. p.542.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/25\">",
"      Downs JB, Rackstein AD, Klein EF Jr, Hawkins IF Jr. Hazards of radial-artery catheterization. Anesthesiology 1973; 38:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/26\">",
"      Singh S, Nelson N, Acosta I, et al. Catheter colonization and bacteremia with pulmonary and arterial catheters. Crit Care Med 1982; 10:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/27\">",
"      Raad I, Umphrey J, Khan A, et al. The duration of placement as a predictor of peripheral and pulmonary arterial catheter infections. J Hosp Infect 1993; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/28\">",
"      Band JD, Maki DG. Infections caused by aterial catheters used for hemodynamic monitoring. Am J Med 1979; 67:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/29\">",
"      Frezza EE, Mezghebe H. Indications and complications of arterial catheter use in surgical or medical intensive care units: analysis of 4932 patients. Am Surg 1998; 64:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/30\">",
"      Norwood SH, Cormier B, McMahon NG, et al. Prospective study of catheter-related infection during prolonged arterial catheterization. Crit Care Med 1988; 16:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/31\">",
"      Cobb DK, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med 1992; 327:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/32\">",
"      Thomas F, Burke JP, Parker J, et al. The risk of infection related to radial vs femoral sites for arterial catheterization. Crit Care Med 1983; 11:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/33\">",
"      Lorente L, Santacreu R, Mart&iacute;n MM, et al. Arterial catheter-related infection of 2,949 catheters. Crit Care 2006; 10:R83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/34\">",
"      Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med 1996; 24:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/35\">",
"      Eyer S, Brummitt C, Crossley K, et al. Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med 1990; 18:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/36\">",
"      Gillies D, O'Riordan L, Wallen M, et al. Optimal timing for intravenous administration set replacement. Cochrane Database Syst Rev 2005; :CD003588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/37\">",
"      Chang C, Dughi J, Shitabata P, et al. Air embolism and the radial arterial line. Crit Care Med 1988; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/38\">",
"      Hansen K. Transthoracic echocardiogram and transcranial doppler detection of emboli after foam sclerotherapy of leg veins. J Vasc Ultrasound 2007; 31:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/39\">",
"      Peruzzi WT, Parker MA, Lichtenthal PR, et al. A clinical evaluation of a blood conservation device in medical intensive care unit patients. Crit Care Med 1993; 21:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/40\">",
"      Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/41\">",
"      Silver MJ, Jubran H, Stein S, et al. Evaluation of a new blood-conserving arterial line system for patients in intensive care units. Crit Care Med 1993; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/42\">",
"      Shapiro BA, Mahutte CK, Cane RD, Gilmour IJ. Clinical performance of a blood gas monitor: a prospective, multicenter trial. Crit Care Med 1993; 21:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/43\">",
"      Menzel M, Henze D, Soukup J, et al. Experiences with continuous intra-arterial blood gas monitoring. Minerva Anestesiol 2001; 67:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/44\">",
"      Russell JA, Joel M, Hudson RJ, et al. Prospective evaluation of radial and femoral artery catheterization sites in critically ill adults. Crit Care Med 1983; 11:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/45\">",
"      Martin C, Saux P, Papazian L, Gouin F. Long-term arterial cannulation in ICU patients using the radial artery or dorsalis pedis artery. Chest 2001; 119:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/46\">",
"      Groell R, Schaffler GJ, Rienmueller R. The peripheral intravenous cannula: a cause of venous air embolism. Am J Med Sci 1997; 314:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/47\">",
"      O'Malley MK, Rhame FS, Cerra FB, McComb RC. Value of routine pressure monitoring system changes after 72 hours of continuous use. Crit Care Med 1994; 22:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/48\">",
"      Finnie KJ, Watts DG, Armstrong PW. Biases in the measurement of arterial pressure. Crit Care Med 1984; 12:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/49\">",
"      Cohn JN. Blood pressure measurement in shock. Mechanism of inaccuracy in ausculatory and palpatory methods. JAMA 1967; 199:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/50\">",
"      Johnson CJ, Kerr JH. Automatic blood pressure monitors. A clinical evaluation of five models in adults. Anaesthesia 1985; 40:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/51\">",
"      Lindqvist A. Beat-to-beat agreement of non-invasive finger artery and invasive radial artery blood pressure in hypertensive patients taking cardiovascular medication. Clin Physiol 1995; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/52\">",
"      Farquhar IK. Continuous direct and indirect blood pressure measurement (Finapres) in the critically ill. Anaesthesia 1991; 46:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/53\">",
"      Aitken HA, Todd JG, Kenny GN. Comparison of the Finapres and direct arterial pressure monitoring during profound hypotensive anaesthesia. Br J Anaesth 1991; 67:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/54\">",
"      Veremakis C, Holloran TH. The technique of monitoring arterial blood pressure. J Crit Illn 1989; 4:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/55\">",
"      Gardner RM. Direct arterial pressure monitoring. Curr Anaesth Crit Care 1990; 1:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/56\">",
"      Boutros A, Albert S. Effect of the dynamic response of transducer-tubing system on accuracy of direct blood pressure measurement in patients. Crit Care Med 1983; 11:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/57\">",
"      Gardner RM, Hollingsworth KW. Optimizing the electrocardiogram and pressure monitoring. Crit Care Med 1986; 14:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26424/abstract/58\">",
"      Gardner RM. Accuracy and reliability of disposable pressure transducers coupled with modern pressure monitors. Crit Care Med 1996; 24:879.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8174 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26424=[""].join("\n");
var outline_f25_51_26424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSERTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Site selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ultrasound guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Separate-guidewire",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Integral-guidewire",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Direct puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      All sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Air embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Iatrogenic blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Site-specific",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BLOOD PRESSURE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sources of error",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dynamic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Transducer position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Calibration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8174|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/17/14616\" title=\"figure 1\">",
"      Radial artery catheterization techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/57/5021\" title=\"figure 2\">",
"      Arterial catheter rapid flush test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8174|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/7/25723\" title=\"table 1\">",
"      Equipment for arterial line insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/55/33659\" title=\"table 2\">",
"      Complications of arterial catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/48/31499\" title=\"table 3\">",
"      Prevention of infection with arterial catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=related_link\">",
"      Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26425="QT dispersion: Measurement and interpretation";
var content_f25_51_26425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   QT dispersion: Measurement and interpretation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Velislav Batchvarov, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26425/contributors\">",
"     A John Camm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/51/26425/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/51/26425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;QT dispersion (maximum QT interval minus minimum QT interval) was originally proposed as an index of the spatial dispersion of ventricular recovery times. In reality, QT dispersion is a crude and approximate measure of a general abnormality of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to characterize and quantify the inhomogeneity of ventricular repolarization from the surface electrocardiogram (ECG) using precise mathematical methods, such as principal component analysis of the T wave, can be traced back to the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/2\">",
"     2",
"    </a>",
"    ]. In clinical practice, however, the ECG assessment of ventricular repolarization has been limited to the measurement of the QT interval and its heart rate-corrected value (QTc) and to the description of the ST-T morphology, often using vague terms such as \"non-specific ST-T wave changes.\"",
"   </p>",
"   <p>",
"    The QT interval duration varies between leads on the standard ECG, Frank orthogonal leads, and body surface potential maps [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. These interlead differences, called QT interval dispersion or QT range, were proposed as an index of the spatial dispersion of the ventricular recovery times [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/9\">",
"     9",
"    </a>",
"    ]. This measurement was an attempt to distinguish between myocardium that is homogeneous from myocardium that displays inhomogeneity, which is accompanied by increased dispersion of the ventricular recovery times and prolongation of repolarization.",
"   </p>",
"   <p>",
"    However, there has been much concern about the validity of the concept and the methodology of the measurement. Despite ongoing controversy, there are a number of reasonable conclusions about the reliability and applicability of the technique [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The pathophysiology and measurement of QT dispersion will be reviewed here. The clinical applications of QT dispersion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF QT DISPERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial concept that QT dispersion is an index of inhomogeneity was supported by the link between the dispersion of ventricular recovery times and the genesis of arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. It was generally believed that the standard 12-lead ECG contained information about regional ventricular repolarization; thus, when increased QT dispersion was seen in cardiac diseases in which ventricular recovery times were known to be heterogeneous, it was assumed that increased QT dispersion was a direct reflection of the disparity of ventricular recovery times [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The validity of this concept required evidence that monophasic action potentials (MAPs) correlated with body surface ECG features [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/9\">",
"     9",
"    </a>",
"    ]. Experimental and clinical studies have shown a significant correlation between the dispersion of ventricular recovery times, measured with MAPs, and QT dispersion and other electrocardiographic indices of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. These observations seemed to provide proof that QT dispersion directly reflects the dispersion of ventricular recovery times.",
"   </p>",
"   <p>",
"    Despite the correlation between MAP and QT dispersion, it was suggested that QT dispersion could simply reflect variation in the duration of the spatial T loop projections onto the separate ECG leads [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/20\">",
"     20",
"    </a>",
"    ]. Two findings support this \"projection\" theory:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QT dispersion can also be found in the so-called \"derived\" 12-lead ECG (a 12-lead ECG that is reconstructed from the X,Y,Z leads) and therefore contains no regional information; the QT dispersion in the originally recorded and in the \"derived\"12-lead ECG was surprisingly similar [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are significant differences in QT dispersion between patients with narrow and wide T loops [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/23\">",
"       23",
"      </a>",
"      ]. The difference between the QT interval in each of the six limb or six precordial leads and the maximum QT interval in these leads was greatest when the angle between the axis of the lead and the axis of the terminal part of the T loop was greatest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these observations, several other experimental studies did not show a significant correlation between directly measured dispersion of the ventricular recovery times and QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new ECG processing technique has been proposed to distinguish the T wave signals which represent the three-dimensional movement of the ECG dipole from the non-dipolar components; it is the latter that probably represents regional heterogeneity of myocardial repolarization. In one report, the power of the proportion of non-dipolar components within all T wave components, termed relative T wave residua (TWR), differed significantly among different clinical groups of patients, but were only weakly correlated with QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was the first attempt to quantify the content of the local repolarization signals of the electrocardiogram. However, local repolarization signals seemed to constitute only a negligible proportion of the total repolarization content, from 0.03 percent of the total power in normal subjects to &lt;0.2 percent in patients with acute myocardial infarction. Their routine detection and quantification would probably require significant enhancement of the presently available signal-detection techniques.",
"   </p>",
"   <p>",
"    Directly measured dispersion of ventricular recovery times and QT dispersion seem to be correlated without any definitive mechanistic link. General abnormalities of ventricular repolarization, including those leading to regional dispersion of recovery times, modify the spatial T wave loop. As a result of any abnormality, the variations in the projections of the loop onto the individual ECG leads may be increased and the terminal points of the T wave in the ECG tracings may become more difficult to be localized.",
"   </p>",
"   <p>",
"    The effect of local dispersion of repolarization on the morphology of the T wave loop could explain the link between MAP recordings and QT dispersion. Thus, T wave loop dynamics and the variable projections of the loop onto individual ECG leads seem to be the true mechanism for QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The link between T loop morphology and QT dispersion is an old idea. It has been long known that the more abnormal the T wave morphology is in ECG separate leads, the more difficult and less reliable the exact localization of the T wave offset in each lead becomes and the greater the likelihood of increased QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, variations of the T loop morphology may lead to both true variations in the length of the projections of the T loop onto the separate leads and increased measurement-related variations of the QT interval (",
"    <a class=\"graphic graphic_figure graphicRef79885 \" href=\"UTD.htm?6/12/6336\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF QT DISPERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, an accurate assessment of QT dispersion requires all 12 leads of the ECG to be recorded simultaneously in order to avoid the effect of heart rate changes on QT dynamics. As a result, simultaneous 12-lead recordings have been proposed as the gold standard for the measurement of QT dispersion. Since rate-related changes in the QT interval develop slowly, QT dispersion measurements based upon simultaneous recording of six or even only three QRS complexes during ectopic-free sinus rhythm is acceptable for practical purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/28\">",
"     28",
"    </a>",
"    ]. This approach, however, has never been properly validated.",
"   </p>",
"   <p>",
"    In addition to the original expression of QT dispersion as the range of QT interval duration in all measurable leads, many other measurement possibilities have been proposed. To mitigate the effect of outliers in the QT interval data, standard deviation of the QT interval duration in all leads [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/29\">",
"     29",
"    </a>",
"    ], coefficient of variation (SD of",
"    <span class=\"nowrap\">",
"     [QT/QT",
"    </span>",
"    average] x 100), and the so-called \"relative QT dispersion\" have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the range and standard deviation values correlate very closely [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/29,31\">",
"     29,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reliability of QT measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual determination of the end of the T wave and, therefore, manual measurement of the QT interval are unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The main sources of error are specific morphological patterns, low T wave amplitude, and merging of the T wave with U wave or P wave.",
"   </p>",
"   <p>",
"    Several algorithms for automatic determination of the end of the T wave have been proposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The threshold methods localize the T wave offset as an interception of the T wave or one of its differentials with a threshold above the isoelectric line, usually expressed as a percentage of the T wave amplitude. With the threshold methods, the amplitude of the T wave influences the measurement results (",
"      <a class=\"graphic graphic_figure graphicRef79885 \" href=\"UTD.htm?6/12/6336\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Another group of algorithms determine the T wave offset as an interception between a line characterizing the slope of the descending part of the T wave with the isoelectric line, or a threshold line above it. The slope-characterizing line can be a tangent to the point of steepest slope, a straight line through the latter point and the peak of the T wave, a straight line fitted through a region containing the point of steepest slope and several samples of the T wave around it, and possibly other lines. With this method, the measured values of the QT interval depend upon the shape of the descending part of the T wave (",
"      <a class=\"graphic graphic_figure graphicRef57025 \" href=\"UTD.htm?30/62/31727\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other algorithms for automatic QT measurement have been suggested, such as using the maximum curvature [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/26\">",
"       26",
"      </a>",
"      ]. The same tangent method applied to T waves with different morphology of the descending limb, or the same threshold method applied to T waves with different amplitudes, will lead to different measurement errors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the amplitude of the T wave strongly influences the reliability of both automatic and manual measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Different measurement errors are seen when the same tangent method is applied to T waves with different amplitudes or when the same threshold method cuts off the same proportion of the final part of T waves with different amplitudes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effect of U waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal U wave, which is most prominently seen in leads V4-V6 on the surface ECG, is a small rounded deflection (&le;1 mm) following the T wave; it usually has the same polarity of the T wave. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/262?source=see_link\">",
"     \"Basic principles of electrocardiographic interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The origin of the U wave is still disputed. The popular theory attributing the U wave to delayed repolarization of the His-Purkinje fibers has been superseded by the mechanoelectric coupling theory and the M-cell theory [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. M-cells appear to be a hybrid between Purkinje and ventricular cells; their action potential prolongs disproportionately relative to the action potential of other ventricular myocardial cells in response to a slowing of rate or in response to drugs that prolong the action potential duration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the origin of the U wave, what is often interpreted as a pathologically augmented U wave or \"T-U complex\" is actually a prolonged biphasic T wave with an interrupted ascending or descending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/42\">",
"     42",
"    </a>",
"    ]. It is likely that the mechanisms responsible for the usual \"physiologic\" U wave are different from those leading to abnormal gross U waves, as seen in congenital and acquired long QT syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is often difficult, if not impossible, to separate the end of a normal T wave from an obvious U wave. Various patterns in which the T and U waves merge have been described and methods for determining the end of the T wave when it is \"buried\" within the U wave have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/43\">",
"     43",
"    </a>",
"    ]. Depending upon the pattern of T-U wave merging, either the point of intersection of the tangent to the steepest point of the down slope and the isoelectric line, or the nadir between the T and the U wave is closer to the \"real\" T wave end.",
"   </p>",
"   <p>",
"    Studies using manual QT measurements continue to refer to the tangent method without any justification, since the tangent method was proposed merely as an attempt to determine the true end of the T wave in cases of partial merging of T and U [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/43\">",
"     43",
"    </a>",
"    ]. Manual measurement is even less reliable for certain patterns of T-U merging (eg, when the T wave is flat or inverted and the U wave augmented).",
"   </p>",
"   <p>",
"    Repolarization patterns of complex morphology are frequently classified differently by different observers, leading to substantial variability of the measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/37,44,45\">",
"     37,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect of Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dispersion of the Q wave may influence QT dispersion even though it is significantly smaller than the dispersion of T wave offset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Traditional manual measurement, as well as those of some computer algorithms, assesses the Q wave onset separately in each lead, while other computer algorithms use a common, lead independent Q onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This may account for part of the variability in the results obtained with different computer algorithms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Influence of heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies, including large prospective evaluations, used the so-called \"corrected QT (QTc) dispersion\" (ie, the dispersion of the QT intervals corrected for heart rate by some correction formula) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The application of linear formulas for heart-rate correction of the QT interval results in identical values for QT dispersion and QTc dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]; however, this is not true for the non-linear formulas.",
"   </p>",
"   <p>",
"    Although experimental and clinical data have shown that the rate, rhythmicity, and the site of impulse origin can influence the dispersion of ventricular recovery times, this has not been shown for QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Clinical and experimental studies have failed to find significant correlation between heart rate and the dispersion of ventricular recovery times measured with MAPs or QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, QT dispersion is increased with premature beats compared to normal sinus beats [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact relation between the heart rate and dispersion of recovery times is still an unresolved issue. It is clear, however, that QT dispersion measured in the standard 12-lead ECG does not depend upon, and therefore should not be corrected for, the heart rate in the same way as the QT interval. Even more important, dispersion of the corrected QT intervals may differ among different clinically defined groups of patients simply due to application of the Bazett formula in the presence of different heart rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=see_link&amp;anchor=H10#H10\">",
"     \"ECG tutorial: ST and T wave changes\", section on 'Prolonged Q-T interval'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Influence of the number of leads and the lead system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of measurable leads on a standard ECG influences the range of QT interval durations. Some researchers proposed a correction factor, dividing the QT interval range by the square root of the number of measurable ECG leads, the so-called \"adjusted QT dispersion\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/29\">",
"     29",
"    </a>",
"    ]. One study found that this formula led to a reasonable correction in normal ECGs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/29\">",
"     29",
"    </a>",
"    ]. However, while the correction led to maintenance of mean values, substantial individual errors were caused by omitting separate leads. As a result, it is not appropriate to compare results based upon QT interval values measured in ECGs that have used a different number of measurable leads.",
"   </p>",
"   <p>",
"    The value of QT dispersion is maintained when measured in the six precordials instead of the 12 standard ECG leads. Other lead combinations, such as the orthogonal leads (X,Y,Z) or quasiorthogonal leads (I, aVF, V2), have also been studied. Although QT dispersion is decreased when a smaller number of leads is used for QT measurement, QT dispersion differences among various patients groups can still be detected when using the three leads most likely to contribute to QT dispersion (aVF, V1, and V4), the limb leads, the orthogonal leads, or the quasiorthogonal leads [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/21,61-63\">",
"     21,61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is clear that any lead combination can detect general abnormalities in repolarization (ie, in the morphology of the T loop) and translate them into increased values of QT dispersion. However, the likelihood of finding increased QT dispersion is increased when more projections of the T loop onto different leads with different axes are used. Unfortunately, as mentioned above, this does not directly translate into increased regional heterogeneity of recovery times. As a result, there seems to be little justification for continuing the quest for the perfect lead combination for the measurement of QT dispersion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Variability of QT dispersion measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is high interobserver and intraobserver variability of manually measured QT dispersion in normal subjects and patients with various cardiac diseases; relative errors have ranged from less than 5 percent to up to 25 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/25,44,64\">",
"     25,44,64",
"    </a>",
"    ]. In contrast, the relative error with manual measurement of the QT interval is less than 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/64\">",
"     64",
"    </a>",
"    ]. Variations in the results can also be attributed to differences in the measurement method such as manual measurement with a caliper or ruler, application of a digitizing board with or without magnification, on screen measurement with electronic calipers, the noise level, and the paper speed at which the ECGs were recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/33,65\">",
"     33,65",
"    </a>",
"    ]. Even \"gold standard\" manual interval measurement, using a digitizing board, can produce interobserver variations corresponding to purely error-related QT dispersion &gt;40 ms or &gt;60 ms in 20 and 10 percent of observers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reproducibility has not been superior with automatic methods for QT measurement. In one study, for example, the reproducibility from sequentially recorded ECGs of various QT dispersion indices measured with a down slope tangent method in healthy volunteers varied between 16 and 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/31\">",
"     31",
"    </a>",
"    ]. Most available computer algorithms determine the end of the T wave either as an intersection between a tangent to the descending part of the T wave and the isoelectric line or as a point at which the T wave (or its differential) falls below a given threshold (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Reliability of QT measurements'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/67\">",
"     67",
"    </a>",
"    ]. Factors accounting for variability include signal processing options, the way in which the tangent is characterized, the definition of an isoelectric line, or the threshold level. Some software packages offer a large variety of parameter settings; in one, there are more than 100 programmable options for the T wave end localization.",
"   </p>",
"   <p>",
"    Several studies have tried to validate automatic algorithms by comparing them to manual measurement by experienced ECG readers; the results were disappointing, as significant differences were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/42,68-70\">",
"     42,68-70",
"    </a>",
"    ]. One report, for example, investigated the agreement between automatic (downslope inflex tangent method) and manual QT interval measurements in normal subjects and patients with hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/69\">",
"     69",
"    </a>",
"    ]. The agreement between the two methods for measurement of the QT interval, expressed as a correlation coefficient, was relatively poor, being lower in normal subjects than in patients with hypertrophic cardiomyopathy; not surprisingly, the agreement between automatic and manual measurement of QT dispersion was even worse.",
"   </p>",
"   <p>",
"    A few reports have compared different algorithms for automatic QT measurement and substantial differences have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/67,71,72\">",
"     67,71,72",
"    </a>",
"    ]. One study compared two threshold and two slope based techniques, and a validated manual measurement; the results of the mean measurements with different algorithms varied up to 62 ms, which was greater than the manual interobserver variability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/67\">",
"     67",
"    </a>",
"    ]. The threshold algorithm demonstrated the largest variability and its results depended on filtering and algorithm parameters.",
"   </p>",
"   <p>",
"    A second study evaluated the differences between the down slope tangent method, using different number of samples around the inflex point for computation of the tangent, and the modifications of the threshold method were substantial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/72\">",
"     72",
"    </a>",
"    ]. The results varied significantly less with the different settings of the tangent method than with the threshold methods; there were differences of up to 60 ms in normal subjects and up to 70 ms in patients with hypertrophic cardiomyopathy. Thus, only comparison of results obtained with the same automatic methods and with the same parameter setting is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRANSMURAL DISPERSION AND THE TPE INTERVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interval from the peak to the end of the T wave has been referred to as the Tpe interval. This parameter has been evaluated as a surface ECG measure of the transmural dispersion of ventricular repolarization and also of arrhythmic risk.",
"   </p>",
"   <p>",
"    The ratio between the Tpe interval and the QT interval",
"    <span class=\"nowrap\">",
"     (Tpe/QT",
"    </span>",
"    ratio) has also been proposed as a noninvasive marker of the arrhythmic risk instead of the Tpe interval [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/73\">",
"     73",
"    </a>",
"    ]. While both the QT interval as well as the Tpe interval increase across different species with various body sizes as the body mass increases (possibly due to increase in TDR with increase in body mass), the",
"    <span class=\"nowrap\">",
"     Tpe/QT",
"    </span>",
"    ratio remains relatively constant within a narrow range of values between 0.17 and 0.23. In the same publication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/73\">",
"     73",
"    </a>",
"    ], the",
"    <span class=\"nowrap\">",
"     Tpe/QT",
"    </span>",
"    ratio was reported to be relatively stable when the heart varied between 60 and 100 beats per minute in 60 healthy individuals (range 0.15 to 0.25, median 0.21, mean 0.21 &plusmn; 0.003).",
"   </p>",
"   <p>",
"    The T wave on the surface ECG results from transmural (ie, between subendocardial, subepicardial, and possibly midmyocardial M-cells), apicobasal, and transseptal voltage gradients as well as gradients between the left and right ventricle and posterior and anterior ventricular wall [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. The relative contribution of the various gradients to the inscription of the T wave on the surface ECG in the beating human heart, as opposed to experimental preparations (ie, left ventricular wedge preparations), is not established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In left ventricular wedge preparations, the peak of the T wave coincides with the end of epicardial repolarization, whereas the end of the T wave coincides with the end of all ventricular repolarization, which occurs in the mid-myocardial M cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Thus, the Tpe interval may provide a surface ECG approximation of transmural dispersion of repolarization. It has therefore been suggested that the Tpe interval could serve as an ECG marker of arrhythmic risk.",
"   </p>",
"   <p>",
"    However, it is not clear that in beating hearts the Tpe is actually a reflection of the transmural dispersion of repolarization or of other, perhaps more complex, electrophysiologic phenomena. Tpe was initially evaluated in left ventricular wedge preparations that assess only transmural voltage gradients. Furthermore, it is not certain that the degree of transmural dispersion demonstrated in wedge preparations exists in live, beating hearts. Transmural dispersion of repolarization was measured directly using electrograms from five different transmural locations in a series of patients undergoing coronary artery surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/83\">",
"     83",
"    </a>",
"    ]. This failed to demonstrate any significant transmural repolarization gradients at pacing cycle length between 300 ms and 1500 ms and during global ischemia.",
"   </p>",
"   <p>",
"    However, an experimental study with optically mapped AP durations in coronary-perfused scar-free posterior-lateral left ventricular free wall wedge preparations from human hearts with and without heart failure demonstrated significant transmural AP duration gradients during slow pacing in the non-failing hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/84\">",
"     84",
"    </a>",
"    ]. This is the first evidence for the presence of M-cells in the human heart.",
"   </p>",
"   <p>",
"    Studies on intact dog hearts failed to show correlation between transmural dispersion of repolarization and the Tpe interval [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, dispersion of repolarization of the whole heart (measured from various endocardial, epicardial and intramural sites of both ventricles) was highly correlated with the Tpe interval (p&lt;0.0005, r = 0.98), although the latter underestimated total repolarization time by approximately 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/87\">",
"     87",
"    </a>",
"    ]. Endocardial and epicardial maps of both ventricles in pigs and demonstrated that the peak of the T wave coincide with the earliest (but not with epicardial) repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study used both a digital model of the left ventricular wall to simulate the effect of varying action potential durations on the timing of T peak and T end, as well as 1220 simultaneously recorded ECGs and vectorcardiograms (VCGs) from normal cases and patients with myocardial infarction or hypertrophy in order to explain the relationship between the T peak on the ECG and T loop of the VCG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/89\">",
"     89",
"    </a>",
"    ]. The digital model represented an apico-basal slice of the left ventricle, with the subendocardium, midmyocardium, and subepicardium having different action potential duration in accordance with the M-cell model. A marked shortening of the APs in the midmyocardium and subepicardium (simulating ischaemia) had no effect on the T peak, while simulated AP prolongation in the \"M-cell\" region widened the T wave and prolonged the QT interval but without displacement of the T peak. It was concluded that the Tpe interval does not represent transmural dispersion of AP duration. The phase relationship between the ECG and VCG showed that the T peak in the precordial leads was a derivative of the T loop, offering no additional information.",
"   </p>",
"   <p>",
"    Prevailing evidence suggests that Tpe interval reflects more likely total dispersion of repolarization (apico-basal, transmural, global, etc.) rather than just transmural [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between the Tpe interval or",
"    <span class=\"nowrap\">",
"     Tpe/QT",
"    </span>",
"    interval ratio and arrhythmic risk is supported by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/87,90-97\">",
"     87,90-97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Association between increased Tpe or",
"      <span class=\"nowrap\">",
"       Tpe/QT",
"      </span>",
"      interval ratio and arrhythmic risk in LQTS syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/98\">",
"       98",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link\">",
"       \"Pathophysiology of the long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An association of Tpe interval prolongation with inducibility of ventricular arrhythmias during electrophysiology study in patients with structural heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/93,94\">",
"       93,94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Shortening of the Tpe interval during suppression of ventricular ectopics with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Association between Tpe and",
"      <span class=\"nowrap\">",
"       Tpe/QT",
"      </span>",
"      index (see below) and quinidine-induced torsade de pointes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/99\">",
"       99",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H2#H2\">",
"       \"Acquired long QT syndrome\", section on 'Torsades de pointes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gender-specific heart rate-dependence of the Tpe interval with prolongation at slow heart rates [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Correlation of the Tpe interval to the occurrence of sudden cardiac death or ventricular arrhythmias in patients with the Brugada syndrome and hypertrophic cardiomyopathy, and to all-cause mortality in patients undergoing primary PTCA for ST-segment myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/96,97,100\">",
"       96,97,100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other studies showed that prolonged Tpe interval was not associated with increased arrhythmic risk in LQTS patients, or in post-MI patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and in 187 patients with CAD followed-up for up to eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/92,101-103\">",
"     92,101-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Measurement of the Tpe interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been recommended that the Tpe interval should be measured in the precordial leads [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/104\">",
"     104",
"    </a>",
"    ]. In cases of complex (biphasic, triphasic, etc) T waves, the recommendation is to measure the interval from the nadir of the first component of the T wave to the end of the T wave [",
"    <a class=\"abstract\" href=\"UTD.htm?25/51/26425/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In intact hearts, the Tpe interval represents a reliable measure of total dispersion of ventricular repolarization, although it probably underestimates total repolarization time. The relative contribution of different voltage gradients during repolarization (apico-basal, transmural, etc.) to the inscription of the T wave and the Tpe interval is not yet defined. The clinical significance of both Tpe and",
"    <span class=\"nowrap\">",
"     Tpe/QT",
"    </span>",
"    interval ratio remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8867566\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The measurement of QT dispersion (maximum QT interval minus minimum QT interval), originally proposed as an index of the spatial dispersion of ventricular recovery times, is an attempt to distinguish between myocardium that is homogeneous from myocardium that displays inhomogeneity, which is accompanied by increased dispersion of the ventricular recovery times and prolongation of repolarization. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The concept that QT dispersion is an index of inhomogeneity is supported by the link between the dispersion of ventricular recovery times and the genesis of arrhythmias, with some but not all studies having shown a significant correlation between the dispersion of ventricular recovery times, measured with monophasic action potentials, and QT dispersion and other electrocardiographic indices of repolarization. However, others have suggested that QT dispersion could simply reflect variation in the duration of the spatial T loop projections onto the separate electrocardiogram (ECG) leads. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology of QT dispersion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Theoretically, an accurate assessment of QT dispersion requires all 12 leads of the ECG to be recorded simultaneously in order to avoid the effect of heart rate changes on QT dynamics. As a result, simultaneous 12-lead recordings have been proposed as the gold standard for the measurement of QT dispersion. Since rate-related changes in the QT interval develop slowly, however, QT dispersion measurements based upon simultaneous recording of six or even only three QRS complexes during ectopic-free sinus rhythm is acceptable for practical purposes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Measurement of QT dispersion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manual determination of the end of the T wave and, therefore, manual measurement of the QT interval are unreliable, with the main sources of error being morphological patterns, low T wave amplitude, and merging of the T wave with the U wave or P wave. Software that automatically detects the end of the T wave is necessary for this measurement, with the amplitude of the T wave strongly influencing the reliability of both automatic and manual measurements. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Reliability of QT measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although experimental and clinical data have shown that the rate, rhythmicity, and the site of impulse origin can influence the dispersion of ventricular recovery times, this has not been shown for QT dispersion. Clinical and experimental studies have failed to find significant correlation between heart rate and the dispersion of ventricular recovery times measured with MAPs or QT dispersion. The exact relation between the heart rate and dispersion of recovery times is still an unresolved issue. However, QT dispersion measured in the standard 12-lead ECG does not depend upon, and therefore should not be corrected for, the heart rate in the same way as the QT interval. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Influence of heart rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The interval from the peak to the end of the T wave has been referred to as the Tpe interval. The peak of the T wave coincides with the end of epicardial repolarization, whereas the end of the T wave coincides with the end of all ventricular repolarization, which occurs in the mid-myocardial M cells. This parameter has been evaluated as a surface ECG measure of the transmural dispersion of ventricular repolarization and also of arrhythmic risk. However, prevailing evidence suggests that the Tpe interval reflects more likely total dispersion of repolarization (apico-basal, transmural, global, etc.) rather than just transmural dispersion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Transmural dispersion and the Tpe interval'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/1\">",
"      Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/2\">",
"      HORAN LG, FLOWERS NC, BRODY DA. PRINCIPAL FACTOR WAVEFORMS OF THE THORACIC QRS COMPLEX. Circ Res 1964; 15:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/3\">",
"      Wilson FN, Macleod AG, Barker PS, Johnston FD. Determination of the significance of the areas of the ventricular deflections of the electrocardiogram. Am Heart J 1934; 10:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/4\">",
"      Rudehill A, Sundqvist K, Sylv&eacute;n C. QT and QT-peak interval measurements. A methodological study in patients with subarachnoid haemorrhage compared to a reference group. Clin Physiol 1986; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/5\">",
"      Campbell RW, Gardiner P, Amos PA, et al. Measurement of the QT interval. Eur Heart J 1985; 6 Suppl D:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/6\">",
"      Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61:83.",
"     </a>",
"    </li>",
"    <li>",
"     Butrous GS, Dabbas N, Patel PR, et al. Measurement of the QT Interval. In: Clinical Aspects of Ventricular Repolarization, Butrous GS, Schwartz PJ (Eds), Farrand Press, London 1989. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/8\">",
"      Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 1985; 5:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/9\">",
"      Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/10\">",
"      Rautaharju PM. QT and dispersion of ventricular repolarization: the greatest fallacy in electrocardiography in the 1990s. Circulation 1999; 99:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/11\">",
"      HAN J, MOE GK. NONUNIFORM RECOVERY OF EXCITABILITY IN VENTRICULAR MUSCLE. Circ Res 1964; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/12\">",
"      Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. II. The role of nonuniform recovery of excitability in the occurrence of unidirectional block, as studied with multiple microelectrodes. Circ Res 1976; 39:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/13\">",
"      Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983; 67:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/14\">",
"      Kuo CS, Amlie JP, Munakata K, et al. Dispersion of monophasic action potential durations and activation times during atrial pacing, ventricular pacing, and ventricular premature stimulation in canine ventricles. Cardiovasc Res 1983; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/15\">",
"      Kuo CS, Atarashi H, Reddy CP, Surawicz B. Dispersion of ventricular repolarization and arrhythmia: study of two consecutive ventricular premature complexes. Circulation 1985; 72:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/16\">",
"      Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. Br Heart J 1978; 40:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/17\">",
"      Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 1995; 25:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/18\">",
"      Zabel M, Lichtlen PR, Haverich A, Franz MR. Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. J Cardiovasc Electrophysiol 1998; 9:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/19\">",
"      Higham PD, Hilton CJ, Aitcheson JD, et al. Does QT dispersion reflect dispersion of ventricular recovery? (abstract). Circulation 1992; 86(Suppl I):392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/20\">",
"      Coumel P, Maison-Blanche P, Badilini F. Dispersion of ventricular repolarization: reality? Illusion? Significance? Circulation 1998; 97:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/21\">",
"      Macfarlane PW, McLaughlin SC, Rodger JC. Influence of lead selection and population on automated measurement of QT dispersion. Circulation 1998; 98:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/22\">",
"      Lee KW, Kligfield P, Okin PM, Dower GE. Determinants of precordial QT dispersion in normal subjects. J Electrocardiol 1998; 31 Suppl:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/23\">",
"      Kors JA, van Herpen G, van Bemmel JH. QT dispersion as an attribute of T-loop morphology. Circulation 1999; 99:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/24\">",
"      Punske BB, Lux RL, MacLeod RS, et al. Mechanisms of the spatial distribution of QT intervals on the epicardial and body surfaces. J Cardiovasc Electrophysiol 1999; 10:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/25\">",
"      Wang L. QT dispersion from body surface ECG does not reflect the spatial dispersion of ventricular repolarization in sheep. Pacing Clin Electrophysiol 2000; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/26\">",
"      Fuller MS, S&aacute;ndor G, Punske B, et al. Estimates of repolarization dispersion from electrocardiographic measurements. Circulation 2000; 102:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/27\">",
"      Malik M, Acar B, Gang Y, et al. QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization. J Cardiovasc Electrophysiol 2000; 11:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/28\">",
"      Lau CP, Freedman AR, Fleming S, et al. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res 1988; 22:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/29\">",
"      Hnatkova K, Malik M, Kautzner J, et al. Adjustment of QT dispersion assessed from 12 lead electrocardiograms for different numbers of analysed electrocardiographic leads: comparison of stability of different methods. Br Heart J 1994; 72:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/30\">",
"      Hailer B, Van Leeuwen P, Lange S, et al. Corornary artery disease may alter the spatial dispersion of the QT interval at rest. Ann Noninvas Electrocardiol 1999; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/31\">",
"      Gang Y, Guo XH, Crook R, et al. Computerised measurements of QT dispersion in healthy subjects. Heart 1998; 80:459.",
"     </a>",
"    </li>",
"    <li>",
"     McLaughlin NB, Campbell RW, Murray A. Influence of T wave amplitude on automatic QT measurements. In: Computers in Cardiology 1995, IEEE Computer Society Press, 1995. p.777.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/33\">",
"      Murray A, McLaughlin NB, Bourke JP, et al. Errors in manual measurement of QT intervals. Br Heart J 1994; 71:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/34\">",
"      Kors JA, van Herpen G. Measurement error as a source of QT dispersion: a computerised analysis. Heart 1998; 80:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/35\">",
"      Watanabe Y. Purkinje repolarization as a possible cause of the U wave in the electrocardiogram. Circulation 1975; 51:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/36\">",
"      Choo MH, Gibson DG. U waves in ventricular hypertrophy: possible demonstration of mechano-electrical feedback. Br Heart J 1986; 55:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/37\">",
"      Surawicz B. U wave: facts, hypotheses, misconceptions, and misnomers. J Cardiovasc Electrophysiol 1998; 9:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/38\">",
"      Antzelevitch C, Nesterenko VV, Yan GX. Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. J Electrocardiol 1995; 28 Suppl:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/39\">",
"      Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 1991; 68:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/40\">",
"      Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991; 69:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/41\">",
"      Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation 1996; 94:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/42\">",
"      Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998; 98:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/43\">",
"      LEPESCHKIN E, SURAWICZ B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952; 6:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/44\">",
"      Kautzner J, Yi G, Kishore R, et al. Interobserver reproducibility of QT interval measurement and QT dispersion in patients after acute myocardial infarction. Ann Noninvas Electrocardiol 1996; 1:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/45\">",
"      Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/46\">",
"      Macfarlane PW, Devine B, Latif S, et al. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med 1990; 29:354.",
"     </a>",
"    </li>",
"    <li>",
"     Xue Q, Reddy S. New algorithms for QT dispersion analysis. Proceedings of the Marquette 14th ECG Analysis Seminar 1996; 20-23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/48\">",
"      van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990; 29:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/49\">",
"      de Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/50\">",
"      Okin PM, Devereux RB, Howard BV, et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. Circulation 2000; 101:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/51\">",
"      Hodges M, Salerno D, Erlinen D. Bazett's QT correction reviewed: evidence that a linear QT correction for heart rate is better (abstract). J Am Coll Cardiol 1983; 1:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/52\">",
"      Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992; 70:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/53\">",
"      Han J, Millet D, Chizzonitti B, Moe GK. Temporal dispersion of recovery of excitability in atrium and ventricle as a function of heart rate. Am Heart J 1966; 71:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/54\">",
"      Mitchell LB, Wyse DG, Duff HJ. Programmed electrical stimulation studies for ventricular tachycardia induction in humans. I. The role of ventricular functional refractoriness in tachycardia induction. J Am Coll Cardiol 1986; 8:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/55\">",
"      Morgan JM, Cunningham D, Rowland E. Dispersion of monophasic action potential duration: demonstrable in humans after premature ventricular extrastimulation but not in steady state. J Am Coll Cardiol 1992; 19:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/56\">",
"      Maarouf N, Aytemir K, Gallagher M, et al. Is QT dispersion heart rate dependent? What are the values of correction formulas for QT interval? (abstract). J Am Coll Cardiol 1999; 33:113A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/57\">",
"      Zabel M, Woosley RL, Franz MR. Is dispersion of ventricular repolarization rate dependent? Pacing Clin Electrophysiol 1997; 20:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/58\">",
"      Dabrowski A, Kramarz E, Piotrowicz R, Kubik L. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction. Circulation 2000; 101:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/59\">",
"      Day CP, McComb JM, Campbell RW. QT dispersion in sinus beats and ventricular extrasystoles in normal hearts. Br Heart J 1992; 67:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/60\">",
"      Malik M, Camm AJ. Mystery of QTc interval dispersion. Am J Cardiol 1997; 79:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/61\">",
"      Glancy JM, Garratt CJ, Woods KL, De Bono DP. Three-lead measurement of QTc dispersion. J Cardiovasc Electrophysiol 1995; 6:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/62\">",
"      Zareba W, Moss A. Dispersion of repolarization evaluated in three orthogonal-type electrocardiographic leads: L1, aVF, V2 (abstract). Pacing Clin Electrophysiol 1995; 18:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/63\">",
"      Saint Beuve C, Badilini F, Maison-Blanche P, et al. QT dispersion: Comparison of orthogonal, quasi-orthogonal, and 12-lead configurations. Ann Noninvas Electrocardiol 1999; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/64\">",
"      Kautzner J, Yi G, Camm AJ, Malik M. Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol 1994; 17:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/65\">",
"      Tran HT, Fan C, Tu WQ, et al. QT measurement: A comparison of three simple methods. Ann Noninvas Electrocardiol 1998; 3:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/66\">",
"      Malik M, Bradford A. Human precision of operating a digitizing board: implications for electrocardiogram measurements. Pacing Clin Electrophysiol 1998; 21:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/67\">",
"      McLaughlin NB, Campbell RW, Murray A. Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram. Br Heart J 1995; 74:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/68\">",
"      Murray A, McLaughlin NB, Campbell RW. Measuring QT dispersion: man versus machine. Heart 1997; 77:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/69\">",
"      Savelieva I, Yi G, Guo X, et al. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 1998; 81:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/70\">",
"      Vloka ME, Babaev A, Ehlert FA, et al. Poor correlation of automated and manual QT dispersion measurements in patients and normal subjects (abstract). J Am Coll Cardiol 1999; 33:350A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/71\">",
"      McLaughlin NB, Campbell RW, Murray A. Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects. Heart 1996; 76:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/72\">",
"      Batchvarov V, Yi G, Guo X, et al. QT interval and QT dispersion measured with the threshold method depend on threshold level. Pacing Clin Electrophysiol 1998; 21:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/73\">",
"      Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008; 41:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/74\">",
"      Franz MR, Bargheer K, Rafflenbeul W, et al. Monophasic action potential mapping in human subjects with normal electrocardiograms: direct evidence for the genesis of the T wave. Circulation 1987; 75:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/75\">",
"      Higuchi T, Nakaya Y. T wave polarity related to the repolarization process of epicardial and endocardial ventricular surfaces. Am Heart J 1984; 108:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/76\">",
"      Opthof T, Coronel R, Janse MJ. Is there a significant transmural gradient in repolarization time in the intact heart?: Repolarization Gradients in the Intact Heart. Circ Arrhythm Electrophysiol 2009; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/77\">",
"      Patel C, Burke JF, Patel H, et al. Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol 2009; 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/78\">",
"      Rautaharju PM. Dispersed measures of dispersed repolarization and depolarization: scalars, vectors, angles, maps, and prospects for improved clinical utility. J Electrocardiol 2010; 43:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/79\">",
"      Noble D, Cohen I. The interpretation of the T wave of the electrocardiogram. Cardiovasc Res 1978; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/80\">",
"      Wang D, Patel C, Cui C, Yan GX. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther 2008; 119:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/81\">",
"      Yan GX, Lankipalli RS, Burke JF, et al. Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol 2003; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/82\">",
"      Antzelevitch C. Heterogeneity and cardiac arrhythmias: an overview. Heart Rhythm 2007; 4:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/83\">",
"      Taggart P, Sutton PM, Opthof T, et al. Transmural repolarisation in the left ventricle in humans during normoxia and ischaemia. Cardiovasc Res 2001; 50:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/84\">",
"      Glukhov AV, Fedorov VV, Lou Q, et al. Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ Res 2010; 106:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/85\">",
"      Janse MJ, Sosunov EA, Coronel R, et al. Repolarization gradients in the canine left ventricle before and after induction of short-term cardiac memory. Circulation 2005; 112:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/86\">",
"      Opthof T, Coronel R, Wilms-Schopman FJ, et al. Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm 2007; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/87\">",
"      Yamauchi M, Watanabe E, Yasui K, et al. Prevention of ventricular extrasystole by mexiletine in patients with normal QT intervals is associated with a reduction of transmural dispersion of repolarization. Int J Cardiol 2005; 103:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/88\">",
"      Xia Y, Liang Y, Kongstad O, et al. In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. Heart Rhythm 2005; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/89\">",
"      Kors JA, Ritsema van Eck HJ, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008; 41:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/90\">",
"      Lubinskj A, Lewicka-Nowak E, Kempa M, et al. New Insight into Repoiarization Abnormalities in Patients with Congenital Long QT Syndrome: the Increased Transmural Dispersion of Repoiarization. Pacing Clin Electrophysiol 1998; 21[Pt II]:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/91\">",
"      Savelieva I, Yap YG, Yi G, et al. Comparative reproducibility of QT, QT peak, and T peak-T end intervals and dispersion in normal subjects, patients with myocardial infarction, and patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998; 21:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/92\">",
"      Viitasalo M, Oikarinen L, Swan H, et al. Ambulatory electrocardiographic evidence of transmural dispersion of repolarization in patients with long-QT syndrome type 1 and 2. Circulation 2002; 106:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/93\">",
"      Lubinski A, Kornacewicz-Jach Z, Wnuk-Wojnar AM, et al. The terminal portion of the T wave: a new electrocardiographic marker of risk of ventricular arrhythmias. Pacing Clin Electrophysiol 2000; 23:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/94\">",
"      Watanabe N, Kobayashi Y, Tanno K, et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol 2004; 37:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/95\">",
"      Smetana P, Batchvarov V, Hnatkova K, et al. Sex differences in the rate dependence of the T wave descending limb. Cardiovasc Res 2003; 58:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/96\">",
"      Castro Hevia J, Antzelevitch C, Torn&eacute;s B&aacute;rzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/97\">",
"      Shimizu M, Ino H, Okeie K, et al. T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol 2002; 25:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/98\">",
"      Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003; 105:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/99\">",
"      Wu L, Guo D, Li H, et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008; 5:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/100\">",
"      Haarmark C, Hansen PR, Vedel-Larsen E, et al. The prognostic value of the Tpeak-Tend interval in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Electrocardiol 2009; 42:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/101\">",
"      Kanters JK, Haarmark C, Vedel-Larsen E, et al. T(peak)T(end) interval in long QT syndrome. J Electrocardiol 2008; 41:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/102\">",
"      Smetana P, Pueyo E, Hnatkova K, et al. Effect of amiodarone on the descending limb of the T wave. Am J Cardiol 2003; 92:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/103\">",
"      Rubulis A, Bergfeldt L, Ryd&eacute;n L, Jensen J. Prediction of cardiovascular death and myocardial infarction by the QRS-T angle and T vector loop morphology after angioplasty in stable angina pectoris: an 8-year follow-up. J Electrocardiol 2010; 43:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/104\">",
"      Antzelevitch C. T peak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 2001; 31:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/51/26425/abstract/105\">",
"      Emori T, Antzelevitch C. Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol 2001; 12:1369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1026 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26425=[""].join("\n");
var outline_f25_51_26425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8867566\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY OF QT DISPERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEASUREMENT OF QT DISPERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reliability of QT measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effect of U waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect of Q waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Influence of heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Influence of the number of leads and the lead system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Variability of QT dispersion measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRANSMURAL DISPERSION AND THE TPE INTERVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Measurement of the Tpe interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8867566\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1026|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/12/6336\" title=\"figure 1\">",
"      Measurement QT dispersion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31727\" title=\"figure 2\">",
"      QT dispersion tangent method",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/262?source=related_link\">",
"      Basic principles of electrocardiographic interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=related_link\">",
"      Pathophysiology of the long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26426="Treatment of cutaneous leishmaniasis";
var content_f25_51_26426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cutaneous leishmaniasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Naomi Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./treatment-of-cutaneous-leishmaniasis/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./treatment-of-cutaneous-leishmaniasis/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3503298\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmaniasis consists of a complex of vector-borne diseases caused by a heterogeneous group of protozoa belonging to the genus Leishmania; it is transmitted by sand fly vectors. There is a broad array of clinical leishmaniasis syndromes; among these, the clinical course, treatment options, response to therapy, and prognosis are all highly variable. Treatment choices are complicated by the paucity of well-controlled comparative trials and lack of standardized outcome measures [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Old World cutaneous leishmaniasis (CL) consists mainly of L.L. major and L.L. tropica. Less common species include L.L. infantum-chagasi and L.L. aethiopica (",
"    <a class=\"calc graphicRef86988 \" href=\"UTD.htm?0/3/51\">",
"     table 1",
"    </a>",
"    ). New World CL consists mainly of L.L. mexicana, L.L. amazonensis, and Viannia subgenus (",
"    <a class=\"calc graphicRef86988 \" href=\"UTD.htm?0/3/51\">",
"     table 1",
"    </a>",
"    ). Of these species, infection due to L.V. braziliensis and L.V. guyanensis are considered complicated due to risk for mucosal leishmaniasis (ML).",
"   </p>",
"   <p>",
"    The treatment of CL and ML is reviewed here. The clinical features, diagnosis, epidemiology, and control are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23797?source=see_link\">",
"     \"Epidemiology and control of cutaneous leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5914229\">",
"    <span class=\"h1\">",
"     CUTANEOUS LEISHMANIASIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4273845\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cutaneous leishmaniasis (CL) infections eventually resolve clinically without treatment, and not all patients who undergo treatment demonstrate elimination of parasitic infection [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/3\">",
"     3",
"    </a>",
"    ]. The benefits of treatment include accelerated healing of skin lesions [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], reduced likelihood of recurrence (especially in the setting of subsequent immune compromise), diminished severity of skin scarring and attendant emotional concerns [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and reduced risk for metastatic infection (which is important for individuals with immune compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for individuals with infection due to Viannia subgenus) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, in the setting of infection due to the anthroponotic species L.L. tropica, treatment may reduce the reservoir for transmission.",
"   </p>",
"   <p>",
"    The objective of CL treatment is clinical cure, not parasitologic cure. Treatment decisions must include consideration of individual risks and benefits, which can be complex given the large number of parasite species with variable clinical syndromes, complications, and rates of spontaneous resolution. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug resistance varies by region; the same species may have variable response to a given drug depending on the geographic location. In addition, in some endemic areas, access to costly drugs and to species-level diagnosis for guiding treatment is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793911\">",
"    <span class=\"h3\">",
"     Uncomplicated versus complicated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the initial approach to treatment of uncomplicated CL consists of local therapy. Systemic therapy is warranted for treatment of complicated CL; features of complicated CL include [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection with species associated with mucosal leishmaniasis (ML) (primarily Viannia subgenus, especially in the &ldquo;mucosal belt&rdquo; of Bolivia, Peru, and Brazil)",
"     </li>",
"     <li>",
"      More than four lesions of significant size",
"     </li>",
"     <li>",
"      Individual lesions &ge;5 cm",
"     </li>",
"     <li>",
"      Subcutaneous nodules",
"     </li>",
"     <li>",
"      Regional adenopathy &gt;1 cm size",
"     </li>",
"     <li>",
"      Size or location of lesions for which local treatment is not feasible",
"     </li>",
"     <li>",
"      Lesions on face, fingers, or toes",
"     </li>",
"     <li>",
"      Immunosuppressed host",
"     </li>",
"     <li>",
"      Clinical failure of local therapy after two to three months post treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Forms of CL that should be managed as complicated infection with expert consultation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leishmaniasis recidivans (due to L.L. tropica)",
"     </li>",
"     <li>",
"      Disseminated CL (due to L.V. braziliensis)",
"     </li>",
"     <li>",
"      Diffuse CL (due to L.L. mexicana or L.L. amazonensis)",
"     </li>",
"     <li>",
"      Infections due to L.L. aethiopica",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of uncomplicated CL consists of local therapy. This is appropriate for management of Old World CL as well as for treatment of New World CL caused by species unlikely to cause disseminated infection. (See",
"    <a class=\"local\" href=\"#H5913957\">",
"     'Local therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of complicated CL consists of systemic therapy. Speciation of the infecting parasite is helpful in the selection of treatment. Oral systemic agents include azoles and miltefosine; parenteral systemic agents include pentavalent antimonials, amphotericin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H3505033\">",
"     'Overview of therapeutic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4278511\">",
"    <span class=\"h3\">",
"     Spontaneously healing lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients who present with partial or nearly complete spontaneous healing is uncertain. Late in the course of infection, relatively few parasites may be present, and in such circumstances, it is not always possible to identify the infecting species. In general, for Old World CL infection (eg, due to L.L. tropica or L.L. major) and for New World CL infection due to L.L. mexicana, the concern for later complications is relatively low and the lesions often heal in months. CL acquired in Central America, where Viannia subgenus is less frequently associated with ML, may not always require systemic therapy. For such cases, treatment of lesions that appear to be healing spontaneously is not required unless the host is immunocompromised.",
"   </p>",
"   <p>",
"    Balancing the risks and benefits of treatment for patients with CL acquired in South America is more challenging, particularly in the setting of infection acquired in Brazil, Peru, or Bolivia. For these cases, a detailed nasal and oral examination must be performed to exclude mucosal involvement. Biopsy of the lesion with culture and PCR should be pursued, as this may assist with assessment for risk of later mucosal dissemination. Testing the infecting parasite for Leishmania RNA virus (LRV1) to assess risk for later metastatic involvement may be useful although this tool is not routinely available [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of systemic therapy to reduce risk of ML is based on observational evidence; lower rates of ML have been observed among patients who completed CL therapy than among those who received partial or no treatment [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/8\">",
"     8",
"    </a>",
"    ]. However, subsequent development of ML has been observed among individuals treated with antimonials [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. These risks and benefits should be reviewed with patients and a determination regarding treatment should be made based on individual circumstances. Patients who do not receive treatment should be counseled about the signs and symptoms of relapse or ML, and should be followed for one to two years.",
"   </p>",
"   <p>",
"    Among military personnel with L.L. major infection acquired in Iraq, spontaneous healing was observed among more than half of cases after returning home; improved personal hygiene and reduced stress may be relevant factors [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4273805\">",
"    <span class=\"h3\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative CL is a chronic wound [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/14\">",
"     14",
"    </a>",
"    ]. Secondary bacterial infection inhibits healing, permits further enlargement of the lesion, and can cause surrounding cellulitis. Lesions should be gently cleaned with soap and water. If purulence is observed, the overlying eschar should be debrided to a clean base. The wound may be left open to dry, though some favor use of a dry dressing such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    . Trauma may interrupt healing or cause lesions to develop at sites of trauma remote to initial lesion. Cosmetic surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin grafts should be postponed until at least a year after successful healing [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505033\">",
"    <span class=\"h2\">",
"     Overview of therapeutic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic agents and dosing for treatment of CL are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to treatment of CL is often influenced by the agents available. In the United States, there are no therapeutic agents with approval for treatment of CL by the US Food and Drug Administration (FDA). Readily available treatment modalities include cryotherapy and thermotherapy. Relatively few dermatologists have experience treating CL via cryotherapy, and success correlates with experience. Thermotherapy devices may be less accessible; less skill with these devices is required for treatment success. Available systemic agents in the United States include azoles, amphotericin deoxycholate, and liposomal amphotericin. The efficacy of azoles is limited and the duration of treatment is prolonged. Therefore, many use parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    given accessibility and short duration, even though evidence for efficacy is limited and the optimal dose remains uncertain. Use of amphotericin deoxycholate is limited by duration and toxicity, but is quite effective.",
"   </p>",
"   <p>",
"    In the United States, pentavalent antimonials, oral miltefosine, and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (including WR279,396) are not available commercially, but in some cases, may be obtained via investigational new drug (IND) protocols .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1791586\">",
"    <span class=\"h3\">",
"     Local therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local therapy is preferred for treatment of uncomplicated Old World CL, and may be useful for New World CL caused by species unlikely to cause disseminated infection. Eschar(s) overlying ulcers should be d&eacute;brided prior to administration of local therapy to maximize treatment effect. Patients with subcutaneous nodules, regional adenopathy, and infection due to species associated with mucosal involvement should not be treated with local therapy alone as it is unlikely to control the infection.",
"   </p>",
"   <p>",
"    The efficacy of local therapy is greatest using a treatment approach combining cryotherapy immediately followed by intralesional pentavalent antimony, which is widely used globally, but not available in United States. Use of cryotherapy alone is appropriate for relatively small, nonulcerated lesions of recent onset. Thermotherapy alone can be used as an alternative to cryotherapy for management of patients with uncomplicated Old World or New World CL presenting with few and relatively small (&le;25 mm) lesions. Thermotherapy and cryotherapy can also be used for follow-up management of residual lesions not fully healed after systemic treatment; in addition, both are acceptable for use during pregnancy and breast feeding.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    may be used for treatment of",
"    <strong>",
"     ulcerative",
"    </strong>",
"    lesions due to L.L. major or non-ML associated Central American species; it is not generally used in conjunction with cryotherapy or thermotherapy. In the United States, the availability of topical paromomycin is limited to a compounded ointment prepared from capsules; the efficacy of such preparations is uncertain and they have not been studied in clinical trials. WR279,396 (a topical cream containing 15 percent paromomycin and 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) is available under investigational new drug protocol to United States military healthcare beneficiaries.",
"   </p>",
"   <p>",
"    Photodynamic therapy is a relatively new therapy; thus far it appears promising, although data are limited.",
"   </p>",
"   <p>",
"    Specific agents for local therapy are discussed further below. (See",
"    <a class=\"local\" href=\"#H5913957\">",
"     'Local therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2036958\">",
"    <span class=\"h3\">",
"     Oral systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral systemic agents include azoles and miltefosine (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some cases, azoles can be used as first line systemic therapy, although, the efficacy of azole therapy is limited and treatment failure is common. Clinical circumstances in which azoles have been used successfully include lymphocutaneous spread in the setting of non-ML associated infection and cases in which the scope of cutaneous involvement is not amenable to local therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    may be useful for treatment of L.L. major, L.L. mexicana, and possibly L.V. panamensis. Azoles may be used in combination with cryo- or thermotherapy for treatment of L.L. major with lymphocutaneous involvement.",
"   </p>",
"   <p>",
"    Oral miltefosine has reasonable efficacy against many New World CL species (compared with pentavalent antimonials). Data are limited regarding use of miltefosine for Old World CL, but it appears to have some efficacy. In the United States, miltefosine is available only via an investigator-sponsored IND protocol.",
"   </p>",
"   <p>",
"    Oral systemic therapy is discussed further below. (See",
"    <a class=\"local\" href=\"#H5913965\">",
"     'Oral systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2036994\">",
"    <span class=\"h3\">",
"     Parenteral systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral agents for treatment of CL include pentavalent antimonials, amphotericin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). Both pentavalent antimonials and amphotericin derivatives have activity against Old World and New World CL. Antimonials are generally the treatment of choice for systemic parenteral therapy of CL, given observed success with antimonials and toxicity associated with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ; further study of liposomal amphotericin is needed. Pentamidine is used largely for treatment of infection due to L.V. guyanensis, but is generally a secondary therapy due to its adverse effect profile.",
"   </p>",
"   <p>",
"    There are two parenteral pentavalent antimony agents: sodium stibogluconate and meglumine antimoniate. The antimonial drugs have good efficacy for reducing risk of progression to mucosal disease in New World CL. Parenteral sodium stibogluconate is the treatment of choice for infection due to Viannia subgenus acquired in South America, especially in the mucosal belt, except for known foci of high antimonial resistance such as Madidi National Park, Bolivia. Treatment with systemic antimonials is also appropriate in the setting of complicated Old World CL that has not responded to local therapy. In the United States, antimonial drugs are available only via an IND protocol.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate has the greatest efficacy against CL (based on case series, not controlled trials), but its use is somewhat limited by toxicity. Liposomal amphotericin circumvents some of the toxicity and may permit a shorter duration of treatment; further studies are needed to fully evaluate its use for treatment of CL, including the appropriate dose and duration.",
"   </p>",
"   <p>",
"    Parenteral systemic therapy is discussed further below. (See",
"    <a class=\"local\" href=\"#H5913973\">",
"     'Parenteral systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2037030\">",
"    <span class=\"h2\">",
"     Specific therapeutic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913957\">",
"    <span class=\"h3\">",
"     Local therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of local therapy is discussed above. (See",
"    <a class=\"local\" href=\"#H1791586\">",
"     'Local therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1791641\">",
"    <span class=\"h4\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of cryotherapy is often restricted to Old World disease since there is no risk for metastases and less lymphocutaneous involvement with these species. Cryotherapy may be used for infection of recent onset (less than three months&rsquo; duration), disease with relatively few and relatively small lesions (&lt;3 cm), nodular lesions, and for individuals who cannot use systemic treatment. The efficacy of cryotherapy in clinical trials ranges from 53 to 100 percent; the efficacy is increased when cryotherapy is used in combination with intralesional pentavalent antimonials [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, cryotherapy with liquid nitrogen consists of a freeze, thaw, freeze cycle, which causes intracellular ice to form, destroying cells, and leads to localized ischemic necrosis. It is important to treat into normal appearing tissue around the lesions. One series including 293 patients in Saudi Arabia described a method of cryotherapy involving placement of a cotton tipped applicator with liquid nitrogen directly on the lesion, freezing 15 to 20 seconds (until 1 to 2 mm of circumferential normal appearing skin appears frozen), thawing 20 to 60 seconds, and freezing again [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/20\">",
"     20",
"    </a>",
"    ]. This sequence was repeated at three-week intervals up to three times or until healing occurred.",
"   </p>",
"   <p>",
"    Adverse effects of cryotherapy include erythema, edema of the perilesional area, occasional blistering, permanent hypopigmentation (in dark-skinned individuals), hyperpigmentation, and scar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505048\">",
"    <span class=\"h4\">",
"     Thermotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatotrophic leishmaniasis species, such as L.L. mexicana, L.L. major, and L.L. tropica, are thermosensitive; their ability to replicate is limited at higher temperatures [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/21\">",
"     21",
"    </a>",
"    ]. Heat treatment of cutaneous leishmaniasis can be delivered by several methods; a radiofrequency instrument, ThermoMed, has received US FDA approval for this purpose. Studies evaluating efficacy of radiofrequency thermotherapy for treatment of CL due to L.L. major, L.L. tropica, L.V. panamensis, and L.V. braziliensis have observed clinical cure rates of 54 to 73 percent at two to three months following treatment [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiofrequency instrument is portable, battery-operated, and delivers superficial heat to 50&deg;C via a set of prongs placed directly on the lesion. The treatment is painful and local anesthesia is required. Prongs are touched to the lesion for 30-second heat intervals in a grid pattern over the lesion as well as a 1- to 2-mm border of normal appearing skin. Most trials have used a single treatment session, although up to three treatments have been reported. The probes are not disposable and require sterilization between patients.",
"   </p>",
"   <p>",
"    Thermotherapy can cause second degree burns; up to a week of topical antibiotic therapy and a wound dressing are warranted. Local pain at the site lasts approximately 24 hours and is comparable to sunburn. Other adverse effects include blistering, oozing, and erythema. In general, the cosmetic outcome is relatively good; little permanent hypopigmentation or significant keloid formation has been observed following thermotherapy, in contrast to cryotherapy.",
"   </p>",
"   <p>",
"    Thermotherapy should not be used for lesions with potential for lymphocutaneous or mucosal spread. It should not be used directly over superficial nerves, cartilage, eyelids, nose, or lips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505062\">",
"    <span class=\"h4\">",
"     Intralesional pentavalent antimony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injection of sodium stibogluconate or meglumine antimoniate is a reasonable approach for treatment of a small number of Old World CL lesions &le;1 cm (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). The treatment is most effective for management of lesions due to CL species not associated with mucosal or lymphocutaneous involvement. The optimal dosing regimen is uncertain; few randomized controlled trials have been performed [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/16,26-28\">",
"     16,26-28",
"    </a>",
"    ]. We favor injection of 0.2 to 5 mL per session every three to seven days (up to three weeks between treatments is also acceptable), in combination with cryotherapy [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/9\">",
"     9",
"    </a>",
"    ]. A total of five to eight treatment sessions (or until clinical healing is observed) is appropriate. The efficacy depends on the technical skill of the treating provider and close follow-up for continued treatments.",
"   </p>",
"   <p>",
"    Treatment consists of injection of up to five sites per lesion with a 25 to 27 gauge needle, for an estimated dose of 0.1 mL per cm",
"    <sup>",
"     2",
"    </sup>",
"    . The needle should be advanced while injecting under pressure into the upper and mid dermis of the lesion and border circumferentially, until the lesion is blanched. The procedure is painful; in adults",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"      lidocaine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"      prilocaine",
"     </a>",
"    </span>",
"    cream may be used, while children may need to be anesthetized. Treatment may be repeated up to five to eight times or until healed. Adverse effects include local allergic reaction, pain, edema, pruritus, and transient erythema. Intralesional antimony should be avoided on fingers, nose, ear, eyelid, and near lip.",
"   </p>",
"   <p>",
"    This route of antimonial administration is not currently allowed under the United States IND protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505069\">",
"    <span class=\"h4\">",
"     Topical paromomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (also called aminosidine) is an aminoglycoside in the form of an ointment or cream (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). Topical paromomycin is most useful for treatment of ulcerative infection due to L.L. major with small (&le;5 cm), relatively few lesions in the absence of lymphocutaneous involvement. A meta-analysis of 14 trials with 1221 patients treated with topical paromomycin noted that paromomycin ointment had therapeutic activity against both Old World and New World CL (relative risk [RR] for clinical cure versus placebo, 2.58 versus 1.01) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/29\">",
"     29",
"    </a>",
"    ]. For treatment of Old World CL, the efficacy of topical paromomycin is comparable to that of intralesional antimonials. For treatment of New World CL, topical paromomycin is inferior to parenteral antimonial therapy (RR 0.67; 95% CI 0.54-0.82) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formulations of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    differ in efficacy and include preparations with methylbenzethonium or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    . An ointment consisting of 15 percent paromomycin and 12 percent methylbenzthonium (Leishcutan) was effective among 87 percent of 67 patients with CL due to L.L. major [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/30\">",
"     30",
"    </a>",
"    ]. Adverse effects included localized pain, skin irritation, and edema. This preparation is not effective for treatment of CL due to L.L. tropica. An ointment of 15 percent",
"    <span class=\"nowrap\">",
"     paromomycin/10",
"    </span>",
"    percent urea in soft white paraffin has been studied in Iran and Tunisia; efficacy was insufficient [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WR279,396 is a topical cream consisting of 15 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    and 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    in a hydrophilic base [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/29,33-35\">",
"     29,33-35",
"    </a>",
"    ]. The drug is administered once daily for 20 days. It has been studied in Panama, Colombia, and Tunisia (L.L. major and L. V. panamensis primarily) and shown to have cure rates of 71 to 99 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/29,33-35\">",
"     29,33-35",
"    </a>",
"    ]. Following treatment, the scar is usually not retracted. Side effects include erythema and mild pain.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    can be compounded in the United States using oral capsules and WR279,396 may be obtained in some cases via IND protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505076\">",
"    <span class=\"h4\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) destroys tissue by generating reactive oxygen species, which interfere with normal cell function. Treatment consists of administration of a photosensitizing compound (such as with 5-aminolaevulinic acid) that selectively accumulates in the target tissue, followed by irradiation.",
"   </p>",
"   <p>",
"    PDT is a relatively new therapy; thus far it appears promising, although data are limited. In one trial including 60 patients with Old World CL treated with PDT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    , or placebo, complete cure after two months was observed more frequently among patients treated with PDT than the other groups (93, 41, and 13 percent, respectively) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/36\">",
"     36",
"    </a>",
"    ]. The cosmetic results of PDT were good, with superficial or minimal scar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913965\">",
"    <span class=\"h3\">",
"     Oral systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of oral systemic therapy is discussed above. (See",
"    <a class=\"local\" href=\"#H2036958\">",
"     'Oral systemic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505614\">",
"    <span class=\"h4\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Azole drugs alter biosynthesis of ergosterol, thereby modifying the components of the Leishmania parasite membrane (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The use of azoles is limited to specific circumstances depending on geography and the infecting species. Parasite speciation is important to tailor the approach to azole therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    has reasonable clinical efficacy for treatment of CL due to L.L. mexicana, L.V. panamensis, and L.L. major [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/5,38,39\">",
"     5,38,39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is effective against L.L. major in Saudi Arabia, although L.L. major in North Africa and Iraq appears to be less responsive to fluconazole; higher doses may improve efficacy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    was more effective than sodium stibogluconate for treatment of L.L. mexicana infection (89 versus 57 percent, respectively) in one study including 120 Guatemalan patients with CL [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/5\">",
"     5",
"    </a>",
"    ]. However, for treatment of L. braziliensis infection, ketoconazole was less effective than sodium stibogluconate (30 versus 96 percent, respectively) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/5\">",
"     5",
"    </a>",
"    ]. In a study including 96 Iranian patients with CL (likely L.L. major), clinical cure rates were higher with ketoconazole than with intralesional meglumine antimoniate (89 versus 72 percent, respectively) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is effective against L.L. major in Saudi Arabia. In one study including 209 patients with L.L. major infection in Saudi Arabia, healing was observed more frequently among patients who received fluconazole (200 mg daily for six weeks) than placebo (59 versus 22 percent) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/40\">",
"     40",
"    </a>",
"    ]. However, L.L. major in North Africa and Iraq appears to be less responsive to fluconazole [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/41\">",
"     41",
"    </a>",
"    ]. In some circumstances, fluconazole may be more effective at higher doses than lower doses. Among 120 patients with L.L. major in Iran, the relative risk of healing was higher among patients on fluconazole 400 mg daily than among patients on fluconazole 200 mg daily (RR 4.57, 95% CI 1.99-10.46) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/42\">",
"     42",
"    </a>",
"    ]. Similarly, among patients with L.V. braziliensis in one study, short-term cure rates were higher among patients on fluconazole 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day than among patients on 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (100 versus 75 percent, respectively) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/43\">",
"     43",
"    </a>",
"    ]; long-term follow-up is essential to assess the treatment effect on preventing mucosal leishmaniasis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has not been superior to placebo for treatment of L.L. major in some Iranian studies, although demonstrating a treatment effect can be difficult in the setting of high rates of spontaneous healing [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Relatively small studies in India and Kuwait have suggested some benefit to use of itraconazole [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    was successful in a case report of a traveler with a single nodular lesion due to L.L. infantum [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505622\">",
"    <span class=\"h4\">",
"     Miltefosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miltefosine is an oral alkylphosphocholine drug known as hexadecylphosphocholine; it has activity against cutaneous, mucosal, and visceral leishmaniasis (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). Miltefosine interacts with parasite membrane constituents and can affect lipid-dependent cell signaling pathways by inhibiting Akt (also known as protein kinase B) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/49\">",
"     49",
"    </a>",
"    ]. Miltefosine also interferes with glycosylphosphatidyl inositol anchors [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most data available for use of miltefosine address treatment of New World CL. The efficacy of miltefosine for treatment of New World CL varies both by species and by geography within a particular species. Miltefosine appears to have clinical utility for treatment of L.V. panamensis, L.V. guyanensis, and L.V. braziliensis infection in Colombia and Brazil [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Miltefosine shows efficacy in the treatment of L.V. braziliensis in Bolivia (88 percent) and Brazil (75 percent), but not in Guatemala (45 percent) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/50,54,55\">",
"     50,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on use of miltefosine for treatment of Old World CL are limited [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Among 63 Iranian patients with L.L. major infection, the efficacy of miltefosine and intramuscular meglumine antimoniate were comparable (81 percent at three months after treatment) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral absorption of miltefosine is relatively slow, and the elimination half-life is 30.9 days [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/58\">",
"     58",
"    </a>",
"    ]. In one study of serial skin biopsies performed during miltefosine treatment, the rate of parasite load decline for L.L. major and L.L. infantum was about one",
"    <span class=\"nowrap\">",
"     log/week,",
"    </span>",
"    and high skin levels of miltefosine were demonstrated at the end of treatment [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal effects of miltefosine include anorexia, nausea, vomiting, or diarrhea; administration of miltefosine with fatty foods may reduce these symptoms, but the effect on bioavailability is not known. Elevated serum transaminases and creatinine concentration may also occur [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/60\">",
"     60",
"    </a>",
"    ]. The use of miltefosine is contraindicated in pregnant women [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/61\">",
"     61",
"    </a>",
"    ]. Women of child-bearing potential should use contraception during treatment and for four months following treatment with miltefosine [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral miltefosine has reasonable efficacy against many New World CL species (compared with pentavalent antimonials); this advantage must be weighed against adverse events, cost, and availability.",
"   </p>",
"   <p>",
"    Miltefosine is not readily available in the United States but may be obtained via investigational new drug protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913973\">",
"    <span class=\"h3\">",
"     Parenteral systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of parenteral systemic therapy is discussed above. (See",
"    <a class=\"local\" href=\"#H2036994\">",
"     'Parenteral systemic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3505637\">",
"    <span class=\"h4\">",
"     Parenteral pentavalent antimony",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two parenteral pentavalent antimony agents: sodium stibogluconate (sodium antimony gluconate, Pentostam) and meglumine antimoniate (N-methyl glucamine antimoniate, Glucantime) (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The pentavalent antimonial drugs affect ATP synthesis and it has been suggested that they inhibit glycolysis, affecting fatty acid oxidation [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/65\">",
"     65",
"    </a>",
"    ]. Sodium stibogluconate has been identified to have effects on cell signaling, leading to increased interferon gamma production in Leishmania-infected macrophages [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The parenteral pentavalent antimony (SbV) agents generally can be considered clinically equivalent, though it is important to note that they contain different antimony concentrations; sodium stibogluconate contains 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    SbV and meglumine antimoniate contains 81",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    SbV [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. For decades, these drugs have been a standard therapy for CL; they are especially important for management of infection with potential for mucosal progression. However, given advances in species diagnostics and availability of new effective agents with lower toxicity, other therapeutic agents are emerging. This is particularly important in the setting of clinical unresponsiveness to therapy, which requires higher doses and longer duration of therapy and can result in increased toxicity.",
"   </p>",
"   <p>",
"    More data are available regarding use of parenteral antimonials for treatment of New World CL than for treatment of Old World CL [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/5,39,71\">",
"     5,39,71",
"    </a>",
"    ]. One meta-analysis including 1150 patients with New World CL noted a comparable cure rate with pentavalent antimonials and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    (76 percent) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/72\">",
"     72",
"    </a>",
"    ]. No differences in efficacy between species were observed (although most infections were due to L.V. braziliensis), but there were differences in efficacy between regions, with greater efficacy in Colombia than Brazil (91 versus 71 percent, respectively) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/72\">",
"     72",
"    </a>",
"    ]. It has been observed that early treatment of New World CL (eg, treatment of patients with only superficial ulceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less than 30 days of illness) with parenteral antimonials does not prevent ulceration and is associated with high rates of treatment failure [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of parenteral antimonials for treatment of Old World CL is 60 to 80 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/73\">",
"     73",
"    </a>",
"    ]. Among 64 Iranian patients with likely L.L. major, combination therapy with meglumine antimoniate plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    was more likely to be associated with a complete response rate than meglumine antimoniate plus placebo (81 versus 52 percent) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pentavalent antimonial drugs are administered by intramuscular or intravenous routes for systemic therapy. Dosing for sodium stibogluconate or meglumine antimoniate consists of 20 mg",
"    <span class=\"nowrap\">",
"     SbV/kg/day",
"    </span>",
"    (there is no upper limit, in contrast to the information in the package insert) in a single daily dose infused over 15 to 30 minutes for 20 days. Expert consultation regarding dosage should be pursued for management of obese patients. Pentavalent antimonials accumulate in renal insufficiency. The rate of antimony clearance is higher in children than adults, which may explain why lower antimonial response rates have been observed among children compared with adults [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects include myalgias and arthralgias (these generally occur after seven days of therapy), early elevation of pancreatic enzymes (though clinical pancreatitis occurs less frequently), rash, nausea, abdominal pain, fatigue, headaches, elevated transaminases, mild leukopenia, and nonspecific ST wave changes on electrocardiography [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. Less common findings include anemia, thrombocytopenia, reactivation of herpes simplex and varicella zoster viruses, and QT prolongation [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/82\">",
"     82",
"    </a>",
"    ]. Rare but serious side effects include angioedema and severe pancreatitis [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/83\">",
"     83",
"    </a>",
"    ]. In general, most effects are reversible and management is symptomatic; nonsteroidal drugs may be administered for musculoskeletal pain [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/81\">",
"     81",
"    </a>",
"    ]. In the setting of elevated pancreatic enzymes, the drug should be held for a few days until levels normalize. In general, weekly electrocardiogram and blood counts should be monitored during therapy, in addition to serum concentrations of creatinine, amylase, lipase, and transaminases. The pentavalent antimonial drugs are contraindicated during pregnancy and breast feeding [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic response to treatment of leishmaniasis is influenced by multiple factors, including pharmacologic factors, the host immune status, and the variable biology of Leishmania species. These factors confound correlation of clinical outcomes with drug susceptibility and the possibility of resistance [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/86\">",
"     86",
"    </a>",
"    ]. Diminished response to pentavalent antimony has been observed among L.V. braziliensis, L.L. tropica, and L.L. aethiopica, with some geographic variability. Failure of pentavalent antimonial drugs has been associated with increased duration of skin lesions, multiple lesions, age of patient, large lesions, parasite species, and concomitant helminth infection [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, sodium stibogluconate is available from the United States Centers for Disease Control and Prevention (CDC) Drug Services (404-639-3670) via an IND protocol. For military healthcare beneficiaries, sodium stibogluconate is available at the Walter Reed National Military Medical Center (301-295-6400).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18323512\">",
"    <span class=\"h4\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    used in the treatment of CL: amphotericin B deoxycholate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (Ambisome) (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). Amphotericin B is a polyene antibiotic; the drug binds to ergosterol precursors in preference to host cholesterol, leading to increased parasite membrane permeability resulting in cell death [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate is limited by long duration of intravenous therapy (hours of infusion daily for 20 to 30 days) and potential irreversible nephrotoxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    consists of amphotericin incorporated into liposomes that targets to the drug to macrophages, where the parasite is concentrated; the preparation is also associated with lower rates of nephrotoxicity than amphotericin B deoxycholate. Limited data suggest that patients with ML may benefit from treatment with liposomal amphotericin [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/90\">",
"     90",
"    </a>",
"    ]; this data might be extrapolated to suggest that CL patients treated with liposomal amphotericin may have decreased risk for future ML although further study is needed. Other lipid amphotericin agents have not been studied sufficiently for treatment of CL but reports suggest they may not have equivalent efficacy [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2037869\">",
"     'Mucosal leishmaniasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    include nephrotoxicity, hypokalemia, anemia, peripheral vein phlebitis, and fever with rigors related to infusion. The risk of nephrotoxicity associated with amphotericin B may be increased among patients previously treated with pentavalent antimonials; saline loading may reduce nephrotoxicity [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, baseline QT prolongation may be potentiated in the setting of hypokalemia induced by amphotericin B, which can lead to cardiac arrhythmia; a wash-out period of at least two weeks between the two treatments (antimonials and amphotericin) is warranted [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Additional side effects associated with liposomal amphotericin treatment in CL include infusion related chest or flank pain, dyspnea, urticaria, flushing [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/96\">",
"     96",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate for treatment of cutaneous leishmaniasis is 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or every other day for 20 to 30 days (approximate total dose 20",
"    <span class=\"nowrap\">",
"     mg/kg);",
"    </span>",
"    the World Health Organization recommends 0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 25 to 30 days [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/9\">",
"     9",
"    </a>",
"    ]. Dosing of liposomal amphotericin is uncertain; it is unclear whether the dosing regimen for visceral leishmaniasis is optimal for treatment of CL [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/91,92,97\">",
"     91,92,97",
"    </a>",
"    ]. Some efficacy has been observed with administration of relatively short course of liposomal amphotericin (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for five consecutive days and a sixth dose on day 10); further study is needed [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the efficacy of amphotericin relative to antimonials are limited [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. In a controlled trial of low dose liposomal amphotericin (1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for five doses) versus meglumine antimoniate (20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    IV for 20 doses) among 35 Brazilian patients with cutaneous leishmaniasis, cure rates were 50 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/100\">",
"     100",
"    </a>",
"    ]. In a case series including patients with L.V. braziliensis",
"    <em>",
"    </em>",
"    CL, 34 patients were treated with liposomal amphotericin (3",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for six doses) and 34 patients treated with sodium stibogluconate (20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for three weeks). Healing was observed in 97 and 71 percent of patients, respectively, and liposomal amphotericin was better tolerated than sodium stibogluconate [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/98\">",
"     98",
"    </a>",
"    ]. In smaller series including patients with Old World CL, 84 percent responded to liposomal amphotericin (3",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    six or more doses) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/96,101\">",
"     96,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4278661\">",
"    <span class=\"h4\">",
"     Pentamidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     Pentamidine",
"    </a>",
"    isoethionate is an alternative parenteral treatment for cutaneous leishmaniasis (",
"    <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"     table 2",
"    </a>",
"    ). It is an aromatic diamidine compound; its mechanism of action is thought to be through interference with DNA synthesis, modifying the Leishmania kinetoplast morphology and causing fragmentation of mitochondrial membranes [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/102\">",
"     102",
"    </a>",
"    ]. Its many adverse effects have relegated it to a secondary therapy, largely reserved for L.V. guyanensis infection acquired in the Guyanas.",
"   </p>",
"   <p>",
"    Data are limited regarding use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    for treatment of Old World CL. In one small series of 11 European patients with infections due to L.L. tropica, L.L. major, or L.L. infantum, treatment with pentamidine (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IM every other day for three doses) resulted in 73 percent clinical response [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are more data regarding use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    for treatment of New World CL than Old World CL [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/104\">",
"     104",
"    </a>",
"    ]. Pentamidine appears to have greatest efficacy against L.V. guyanensis infection acquired in Guyana, French Guiana, and Suriname; among several studies with different regimens and endpoints (including more than 1000 patients cumulatively), efficacy ranged 73 to 95 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/105-110\">",
"     105-110",
"    </a>",
"    ]. In studies in Colombia, higher total dosage (either more doses or higher dose) was linked to efficacy of 96 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     Pentamidine",
"    </a>",
"    has a significant adverse event profile, including drug-induced pancreatitis leading to insulin-dependent diabetes, dysglycemia (especially reversible hypoglycemia), hypotension, QT prolongation, hyperkalemia, cytopenias, nephrotoxicity, and elevated liver-associated enzymes. Other adverse events reported include pain at the injection site, sterile abscesses, dysgeusia, myalgias (increased creatine phosphokinase levels), nausea, and headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4273660\">",
"    <span class=\"h2\">",
"     Assessing response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healing of CL is slow and continues after the course of treatment has been completed; lesions are rarely completely healed at the end of treatment. Treatment response is generally assessed by physical appearance; lesion sampling for parasitologic assessment is not necessary if the lesion appears to be healing clinically. By four to six weeks following treatment, the lesion size should be decreased by approximately two-thirds, with improvement in edema and inflammation; ulcers should be re-epithelializing and new lesions should not appear [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/113\">",
"     113",
"    </a>",
"    ]. Ulcers are generally re-epithelialized or &ldquo;clinically cured&rdquo; approximately three months following treatment [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relatively little improvement or worsening while on therapy suggests an inadequate response and an alternate treatment approach should be planned promptly. For management of patients who relapse or do not respond to treatment, consultation with a leishmaniasis expert is warranted.",
"   </p>",
"   <p>",
"    Patients should be followed for 6 to 12 months after treatment to evaluate for relapse. Leishmania DNA has been detected in scars of clinically healed lesions years following treatment, and in some cases, expansion of the parasite in culture can also be achieved [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/3,114\">",
"     3,114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2037869\">",
"    <span class=\"h1\">",
"     MUCOSAL LEISHMANIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal leishmaniasis (ML) occurs most frequently in the New World and is characterized by mucosal destruction. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link&amp;anchor=H83446528#H83446528\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\", section on 'Mucosal leishmaniasis (ML)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ML can be disfiguring and may cause airway compromise; cure is difficult unless ML is identified while mild. There are few randomized controlled trials to guide therapy; a long duration of therapy is required and close follow-up for relapse is warranted. In the setting of laryngeal involvement, cyanosis and dyspnea can develop with initiation of treatment, requiring emergent tracheostomy. Therefore, some favor concurrent administration of systemic steroids with early therapy.",
"   </p>",
"   <p>",
"    Therapeutic options for treatment of ML include parenteral pentavalent antimony drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , and miltefosine (used for treatment of Bolivian ML) (",
"    <a class=\"graphic graphic_table graphicRef88694 \" href=\"UTD.htm?29/61/30684\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, initial management of ML should consist of parenteral pentavalent antimony in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      for synergistic activity [",
"      <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/115\">",
"       115",
"      </a>",
"      ]. The efficacy of pentavalent antimonials in ML is variable depending on geography, severity of presenting infection, parasite species, and duration of treatment [",
"      <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/116-118\">",
"       116-118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is somewhat limited by toxicity, though case series have demonstrated that it is associated with a better response rate and lower relapse rate than pentavalent antimony. The toxicity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      is comparable to that of antimonials, though data are limited regarding the optimal dose and duration of therapy; its use is also limited by cost. Therefore, pending further data, liposomal amphotericin B remains a secondary therapy unless consistent antimonial resistance has been observed in the region where the infection was acquired.",
"     </li>",
"     <li>",
"      Miltefosine has demonstrated good efficacy in the treatment of Bolivian ML.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       Pentamidine",
"      </a>",
"      is rarely used to treat ML given its adverse effect profile during a long course of treatment [",
"      <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review including 68 studies and 271 patients with ML noted an overall treatment efficacy of 67 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/120\">",
"     120",
"    </a>",
"    ]. Pentavalent antimonial drugs were the most commonly used agents; the efficacy among Brazilian, Peruvian, and Panamanian patients was 88, 51, and 51 percent respectively. In a retrospective review of 140 Brazilian patients, meglumine antimoniate was administered to approximately half of patients with a cure rate of 91 percent and a recurrence rate of 22 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/90\">",
"     90",
"    </a>",
"    ]. Primary resistance to antimonials was observed in 14 percent of cases; most resistance was related to use of doses &lt;10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and shorter duration of therapy.",
"   </p>",
"   <p>",
"    Among 23 Brazilian patients with L.V. braziliensis, patients treated with sodium stibogluconate (20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 30 doses) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (400 mg orally three times daily for 30 days) healed faster than those treated with sodium stibogluconate alone (100 versus 40 percent healing at six months following treatment) [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/115\">",
"     115",
"    </a>",
"    ]. The benefit of pentoxifylline may be related to its ability to downregulate TNF-alpha production, which is expressed in high levels in ML lesions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate has therapeutic activity for ML. Among Brazilian and Bolivian patients with mucocutaneous disease, 90 to 96 percent who completed therapy (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    until healing; in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) were clinically cured [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Complete healing was observed among eight Brazilian patients treated with liposomal amphotericin (total dose 35",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    with two years of follow-up [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Miltefosine is effective for treatment of ML due to L.V. braziliensis in Bolivia. Among 72 patients treated with miltefosine (2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 28 doses with one year follow-up), the efficacy for mild and moderate disease was 83 and 58 percent, respectively [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/124\">",
"     124",
"    </a>",
"    ]. A follow-up study extending the duration of therapy to six weeks increased the cure rate to 75 percent [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited regarding treatment of ML due to Old World species such as L.L. aethiopica in",
"    <span class=\"nowrap\">",
"     Sudan/Ethiopia",
"    </span>",
"    or L.L. infantum-chagasi infection [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/126,127\">",
"     126,127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up of ML after treatment should include nasopharyngeal and laryngeal visualization every three months for one year, or longer in the absence of resolution. Evidence of clinical response depends on the initial presentation; signs to follow include erythema, edema, infiltration, ulceration, and tissue destruction. Septal perforation and granulomatous appearing lesions are common. Response is usually seen during treatment, but relapses are common. Consultation with a leishmaniasis expert should be pursued in the absence of treatment response. In some cases, surgical reconstruction may be required; if possible, tissue grafts should be delayed for at least a year after effective treatment [",
"    <a class=\"abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/15,128\">",
"     15,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4289568\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a broad array of clinical leishmaniasis syndromes; among these, the clinical course, treatment options, response to therapy, and prognosis are all highly variable. Treatment choices are complicated by the paucity of well-controlled comparative trials and lack of standardized outcome measures. (See",
"      <a class=\"local\" href=\"#H3503298\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cutaneous leishmaniasis (CL) infections eventually resolve clinically without treatment, and not all patients who undergo treatment demonstrate elimination of parasitic infection. The benefits of treatment include accelerated healing of skin lesions, reduced likelihood of recurrence, diminished severity of scarring, and reduced risk for metastatic infection. (See",
"      <a class=\"local\" href=\"#H4273845\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the initial approach to treatment of uncomplicated CL consists of local therapy. Systemic therapy is warranted for treatment of complicated CL. Features of complicated CL are summarized above. (See",
"      <a class=\"local\" href=\"#H2793911\">",
"       'Uncomplicated versus complicated infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic agents and dosing for treatment of CL are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"       table 2",
"      </a>",
"      ). The approach to treatment of CL is often influenced by the agents available. (See",
"      <a class=\"local\" href=\"#H3505033\">",
"       'Overview of therapeutic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local therapy is preferred for treatment of uncomplicated Old World CL, and may be useful for New World CL caused by species unlikely to cause disseminated infection. Cryotherapy or thermotherapy can be used for the management of patients with uncomplicated Old World or New World CL presenting with few and relatively small (&le;25 mm) lesions. Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      may be used for treatment of",
"      <strong>",
"       ulcerative",
"      </strong>",
"      lesions due to L.L. major or non-ML associated Central American species. (See",
"      <a class=\"local\" href=\"#H1791586\">",
"       'Local therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral systemic agents include azoles and miltefosine (",
"      <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"       table 2",
"      </a>",
"      ). In some cases, azoles can be used as first line systemic therapy, although the efficacy of azole therapy is limited. Oral miltefosine has reasonable efficacy against many New World CL species. Data are limited regarding use of miltefosine for Old World CL, but it appears to have some efficacy. (See",
"      <a class=\"local\" href=\"#H2036958\">",
"       'Oral systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral agents for treatment of CL include pentavalent antimonials, amphotericin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88693 \" href=\"UTD.htm?21/63/22525\">",
"       table 2",
"      </a>",
"      ). Both pentavalent antimonials and amphotericin derivatives have activity against both Old World and New World CL. Antimonials are generally the treatment of choice for systemic parenteral therapy of CL, given observed success with antimonials and toxicity associated with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ; further study of liposomal amphotericin is needed. Pentamidine is used largely for treatment of infection due to L.V. guyanensis, but is generally a secondary therapy due to its adverse effect profile. (See",
"      <a class=\"local\" href=\"#H5913973\">",
"       'Parenteral systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healing of CL is slow and continues after the course of treatment has been completed. Treatment response is generally assessed by physical appearance. By four to six weeks following treatment, the lesion size should be decreased by approximately two-thirds, with improvement in edema and inflammation; ulcers should be re-epithelializing and new lesions should not appear. Relatively little improvement or worsening while on therapy suggests an inadequate response and an alternate treatment approach should be planned promptly. (See",
"      <a class=\"local\" href=\"#H4273660\">",
"       'Assessing response to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucosal leishmaniasis (ML) occurs most frequently in the New World and is characterized by mucosal destruction. Therapeutic options for treatment of ML include parenteral pentavalent antimony drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , and miltefosine (used for treatment of Bolivian ML) (",
"      <a class=\"graphic graphic_table graphicRef88694 \" href=\"UTD.htm?29/61/30684\">",
"       table 3",
"      </a>",
"      ). In general, initial management of ML should consist of parenteral pentavalent antimony, in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      for synergistic activity. The use of amphotericin B is somewhat limited by toxicity, though case series have demonstrated that it is associated with a better response rate and lower relapse rate than pentavalent antimony. (See",
"      <a class=\"local\" href=\"#H2037869\">",
"       'Mucosal leishmaniasis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18323583\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to an earlier version of this topic review.",
"   </p>",
"   <p>",
"    The content and views expressed in this publication are the sole responsibility of the author and do not necessarily reflect the views or policies of the Department of Defense or the US Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/1\">",
"      Gonz&aacute;lez U, Pinart M, Rengifo-Pardo M, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; :CD004834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/2\">",
"      Gonz&aacute;lez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; :CD005067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/3\">",
"      Mendon&ccedil;a MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/4\">",
"      Unger A, O'Neal S, Machado PR, et al. Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg 2009; 80:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/5\">",
"      Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/6\">",
"      Weigel MM, Armijos RX, Racines RJ, et al. Cutaneous leishmaniasis in subtropical Ecuador: popular perceptions, knowledge, and treatment. Bull Pan Am Health Organ 1994; 28:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/7\">",
"      Yanik M, Gurel MS, Simsek Z, Kati M. The psychological impact of cutaneous leishmaniasis. Clin Exp Dermatol 2004; 29:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/8\">",
"      Marsden PD. Mucosal leishmaniasis (\"espundia\" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Technical Report Series 949. &ldquo;Control of the Leishmaniases.&rdquo; 2010. file://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/10\">",
"      Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011; 331:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/11\">",
"      Zangger H, Ronet C, Desponds C, et al. Detection of Leishmania RNA virus in Leishmania parasites. PLoS Negl Trop Dis 2013; 7:e2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/12\">",
"      Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004; 97:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/13\">",
"      Willard RJ, Jeffcoat AM, Benson PM, Walsh DS. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol 2005; 52:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/14\">",
"      Sakthianandeswaren A, Elso CM, Simpson K, et al. The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci U S A 2005; 102:15551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/15\">",
"      Wortmann GW, Aronson NE, Miller RS, et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000; 31:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/16\">",
"      Uzun S, Durdu M, Culha G, et al. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 2004; 90:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/17\">",
"      Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/18\">",
"      Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/19\">",
"      Layegh P, Pezeshkpoor F, Soruri AH, et al. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 2009; 80:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/20\">",
"      al-Majali O, Routh HB, Abuloham O, et al. A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 1997; 36:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/21\">",
"      Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981; 30:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/22\">",
"      Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/23\">",
"      L&oacute;pez L, Robayo M, Vargas M, V&eacute;lez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/24\">",
"      Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4:e628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/25\">",
"      Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/26\">",
"      Solomon M, Baum S, Barzilai A, et al. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol 2009; 23:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/27\">",
"      Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/28\">",
"      Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996; 35:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/29\">",
"      Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009; 3:e381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/30\">",
"      El-On J, Livshin R, Even-Paz Z, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/31\">",
"      Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/32\">",
"      Asilian A, Jalayer T, Whitworth JA, et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/33\">",
"      Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/34\">",
"      Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3:e432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/35\">",
"      Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/36\">",
"      Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/37\">",
"      Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/38\">",
"      Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 2001; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/39\">",
"      Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/40\">",
"      Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/41\">",
"      Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/42\">",
"      Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011; 64:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/43\">",
"      Sousa AQ, Frutuoso MS, Moraes EA, et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/44\">",
"      Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/45\">",
"      Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/46\">",
"      al-Fouzan AS, al Saleh QA, Najem NM, Rostom AI. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol 1991; 30:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/47\">",
"      Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol 1996; 26:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/48\">",
"      Paniz Mondolfi AE, Stavropoulos C, Gelanew T, et al. Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother 2011; 55:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/49\">",
"      Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/50\">",
"      Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/51\">",
"      Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/52\">",
"      V&eacute;lez I, L&oacute;pez L, S&aacute;nchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/53\">",
"      Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/54\">",
"      Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/55\">",
"      Machado PR, Ampuero J, Guimar&atilde;es LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/56\">",
"      Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/57\">",
"      van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/58\">",
"      Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/59\">",
"      Dorlo TP, van Thiel PP, Schoone GJ, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis 2011; 5:e1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/60\">",
"      Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/61\">",
"      Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/62\">",
"      Dorlo TP, Balasegaram M, Lima MA, et al. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/63\">",
"      Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/64\">",
"      Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/65\">",
"      Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987; 36:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/66\">",
"      Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001; 167:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/67\">",
"      Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004; 71:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/68\">",
"      S&aacute;enz RE, Paz HM, Johnson CM, et al. [Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis]. Rev Med Panama 1987; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/69\">",
"      Deps PD, Viana MC, Falqueto A, Dietze R. [Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis]. Rev Soc Bras Med Trop 2000; 33:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/70\">",
"      Saldanha AC, Romero GA, Guerra C, et al. [Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity]. Rev Soc Bras Med Trop 2000; 33:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/71\">",
"      Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 1997; 126:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/72\">",
"      Tuon FF, Amato VS, Graf ME, et al. Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis. Int J Dermatol 2008; 47:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/73\">",
"      Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57:335.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/74\">",
"      Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/75\">",
"      Cruz A, Rainey PM, Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/76\">",
"      Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/77\">",
"      Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/78\">",
"      Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011; 118:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/79\">",
"      Gasser RA Jr, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/80\">",
"      Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/81\">",
"      Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis 2012; 6:e1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/82\">",
"      Wortmann GW, Aronson NE, Byrd JC, et al. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis 1998; 27:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/83\">",
"      McBride MO, Linney M, Davidson RN, Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 1995; 21:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/84\">",
"      Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/85\">",
"      Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/86\">",
"      Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007; 56:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/87\">",
"      Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/88\">",
"      O'Neal SE, Guimar&atilde;es LH, Machado PR, et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 2007; 195:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/89\">",
"      Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990; 34:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/90\">",
"      Amato VS, Tuon FF, Imamura R, et al. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009; 23:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/91\">",
"      Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/92\">",
"      Wortmann GW, Fraser SL, Aronson NE, et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 1998; 26:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/93\">",
"      Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/94\">",
"      Maheshwari A, Seth A, Kaur S, et al. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar. Pediatr Infect Dis J 2011; 30:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/95\">",
"      Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998; 351:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/96\">",
"      Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/97\">",
"      Townsend RW, Zutshi A, Bekersky I. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos 2001; 29:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/98\">",
"      Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2013; 68:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/99\">",
"      Neves LO, Talhari AC, Gadelha EP, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/100\">",
"      Motta JO, Sampaio RN. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2012; 26:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/101\">",
"      Solomon M, Pavlotsky F, Leshem E, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/102\">",
"      Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/103\">",
"      Hellier I, Dereure O, Tournillac I, et al. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 2000; 200:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/104\">",
"      Jaur&eacute;guiberry S, Graby G, Caumes E. Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients. Clin Infect Dis 2006; 42:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/105\">",
"      Low-A-Chee RM, Rose P, Ridley DS. An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983; 77:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/106\">",
"      Pradinaud R, et al. Bilan de 10 annees de traitement de la leishmaniose tegumentaire par la pentamidine en Guyane Francaise: a propos de 1025 cas. Nouv Dermatol 1991; 10:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/107\">",
"      Lightburn E, Morand JJ, Meynard JB, et al. [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate]. Med Trop (Mars) 2003; 63:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/108\">",
"      Lai A Fat EJ, Vrede MA, Soetosenojo RM, Lai A Fat RF. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002; 41:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/109\">",
"      van der Meide WF, Sabajo LO, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol 2009; 48:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/110\">",
"      Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/111\">",
"      Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/112\">",
"      Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/113\">",
"      Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012; 86:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/114\">",
"      Schubach A, Marzochi MC, Cuzzi-Maya T, et al. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 1998; 58:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/115\">",
"      Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/116\">",
"      Saenz RE, de Rodriguez CG, Johnson CM, Berman JD. Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis. Am J Trop Med Hyg 1991; 44:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/117\">",
"      Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/118\">",
"      Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/119\">",
"      Amato V, Amato J, Nicodemo A, et al. [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate]. Ann Dermatol Venereol 1998; 125:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/120\">",
"      Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007; 77:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/121\">",
"      Sampaio SA, Castro RM, Dillon NL, Martins JE. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases. Int J Dermatol 1971; 10:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/122\">",
"      Rodriguez LV, Dedet JP, Paredes V, et al. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1995; 90:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/123\">",
"      Amato VS, Tuon FF, Camargo RA, et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011; 85:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/124\">",
"      Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/125\">",
"      Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009; 81:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/126\">",
"      el-Hassan AM, Meredith SE, Yagi HI, et al. Sudanese mucosal leishmaniasis: epidemiology, clinical features, diagnosis, immune responses and treatment. Trans R Soc Trop Med Hyg 1995; 89:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./treatment-of-cutaneous-leishmaniasis/abstract/127\">",
"      Aliaga L, Cobo F, Mediavilla JD, et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82:147.",
"     </a>",
"    </li>",
"    <li>",
"     Jeronimo SM, Sousa AD, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogen and Practice, 2nd ed, Guerrant RL, Walker DH, Weller PF (Eds), Elsevier, Philadelphia 2006. p.1107.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5686 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-89.32.226.102-CE97BA6EE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26426=[""].join("\n");
var outline_f25_51_26426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4289568\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3503298\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5914229\">",
"      CUTANEOUS LEISHMANIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4273845\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2793911\">",
"      - Uncomplicated versus complicated infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4278511\">",
"      - Spontaneously healing lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4273805\">",
"      - Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3505033\">",
"      Overview of therapeutic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1791586\">",
"      - Local therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2036958\">",
"      - Oral systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2036994\">",
"      - Parenteral systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2037030\">",
"      Specific therapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913957\">",
"      - Local therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1791641\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505048\">",
"      Thermotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505062\">",
"      Intralesional pentavalent antimony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505069\">",
"      Topical paromomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505076\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913965\">",
"      - Oral systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505614\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505622\">",
"      Miltefosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913973\">",
"      - Parenteral systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3505637\">",
"      Parenteral pentavalent antimony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18323512\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4278661\">",
"      Pentamidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4273660\">",
"      Assessing response to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2037869\">",
"      MUCOSAL LEISHMANIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4289568\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18323583\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5686|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/63/22525\" title=\"table 2\">",
"      CL treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/61/30684\" title=\"table 3\">",
"      ML treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23797?source=related_link\">",
"      Epidemiology and control of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_51_26427="Drivers with bundle branch blocks";
var content_f25_51_26427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with bundle branch blocks",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"8\">",
"       <p>",
"        Bundle branch block",
"       </p>",
"       <p>",
"        Axis deviation",
"       </p>",
"      </td>",
"      <td rowspan=\"8\">",
"       Progression of disease in the conduction system can lead to third degree heart block with total loss of electrical connection between the atria and ventricles causing syncope or sudden death",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       Every 2 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Depends on risk from underlying heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes, if:",
"      </td>",
"      <td rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Treated for symptomatic disease (see pacemaker)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       No disqualifying heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by cardiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26427=[""].join("\n");
var outline_f25_51_26427=null;
var title_f25_51_26428="Estimated prevalence rates of intermittent explosive disorder";
var content_f25_51_26428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F67143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F67143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated prevalence rates of intermittent explosive disorder from nationally representative surveys",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lifetime percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        12-month percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        1-month percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         China",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Japan",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         South Africa",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ukraine",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         United States",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Shen YC, Zhang MY, Huang Yq, et al. Twelve month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China.",
"       </li>",
"       <li>",
"        Lee S, Tsang A, Zhang MY, et al. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol Med 2007; 37:61.",
"       </li>",
"       <li>",
"        Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63:669.",
"       </li>",
"       <li>",
"        Coccaro EF, Schmidt CA, Samuels JF, Nestadt G. Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. J Clin Psychiatry 2004; 65:820.",
"       </li>",
"       <li>",
"        Yoshimasu K, Kawakami N, WMH-J 2002-2006 Survey Group. Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. Psychiatry Res 2011; 186:384.",
"       </li>",
"       <li>",
"        Bromet EJ, Gluzman SF, Paniotto VI, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol 2005; 40:681.",
"       </li>",
"       <li>",
"        Fincham D, Grimsrud A, Corrigall J, et al. Intermittent explosive disorder in South Africa: prevalence, correlates and the role of traumatic exposures. Psychopathology 2009; 42:92.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26428=[""].join("\n");
var outline_f25_51_26428=null;
var title_f25_51_26429="US meningococcal disease incidence";
var content_f25_51_26429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meningococcal disease incidence*, by year - United States, 1980-2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Meningococcal disease incidence remained low in 2010, but it continues to cause substantial morbidity and mortality in the United States. The highest incidence of meningococcal disease occurs among infants, with a second peak occurring in late adolescence. In 2005, a quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine was licensed and recommended for adolescents and others at increased risk for disease. In October 2010, a booster dose was added to recommendations for adolescents at age 16 years. In 2010, coverage with one dose of meningococcal conjugate vaccine was 62.7 percent among adolescents aged 13 to 17 years in the United States.",
"    <div class=\"footnotes\">",
"     * Per 100,000 population.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26429=[""].join("\n");
var outline_f25_51_26429=null;
var title_f25_51_26430="Pericardial effusion without tamponade 4 chamber view";
var content_f25_51_26430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77900/4chpeff1_conv.mp4?title=Pericardial+effusion+without+tamponade+4+chamber+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four chamber view from a two-dimensional echocardiogram shows a moderate pericardial effusion (PE) surrounding the right atrium (RA), right ventricle (RV), and left ventricle (LV), but not the left atrium (LA). RA motion is exaggerated, but the chamber is not compressed. At cardiac catheterization, the patient had normal hemodynamics.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26430=[""].join("\n");
var outline_f25_51_26430=null;
var title_f25_51_26431="Grade III HPT retinopathy";
var content_f25_51_26431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade III HPT retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AWkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAoorf0nwpqmoeXIYDbWzjInnBVSPb1osNK+iMCtvQfC+s683/ErsJZYwcGU/Kg/4EcCvWPCvhLw9pwid4De38Z/eNc8qPdV6H+fvXoElyRbjJyg42DgL+A/nWFXE06W+p0U8LOe+h5Fo3wfunkU61qMVuMjMcA3sQfc8A/ga7XSfhv4RsdnmW82oSA8vNIcdfQYFbzyKYiVYFSee/PoaWKd1+dvvhflAPBH+NcNTMJWtFWOyGCitxraTounoslnoumwsCdpWFS34ZHtUjXzmVXUCAEbQEQcHqCPei6nja1UjJP57R/TFZlw6MNrEkjPToSP/ANVc31uc92bqhGOyOpttSIwu87sBW+p9qtSXS3MlvvJfymLqpzjkYOawLTmJJNuCwyw6YNW4HczZbocBS3X8q5aldlKkia5WaG58y2dESQKrw7FZeO/Tg/Sqt9p2majCovNHsbpQCheWFQ2D74/rT7idZZWUuyhVywx0PtTHmj2fJksAAOxzntWUcRNaplOknucvqHw/8L6mwVdOa0lGSWt3K/p0/TrXDa78KvLuAmjX+5jg+Vcrgj/gQ/wr15HQr5xDFUGRg8geuazLSUz6jPcEZUH5c9/QV00sfUj12Mp4SElex4FrXg7XtHDPeafKYVzmWL94mB3yOn41z54r6zmVYYA4c8/wA5+v1rldd8D6HrzzSS2y2s+wFZbbgknuR0P5V30s0i/jRxVMG18J860V23in4d6toq+fbD7fZ/34V+df95e34ZrijwcGvShUjUXNF3Rxyi4uzEoooqyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArT0HRL/Xb0W2m27Sv/E3RUHqx7Cug8IeAdT14R3M6mz084PmyLhpB/sDv9ffvXufhuyt9Hs0tNPtkgt0wJFxySBjc3qTWdWrGiryN6OHlVemxyfhX4e6Zopt5b1Dd6krhjI/CREHqF749TnNdhfqkkQSSMMnRRj5Tx29PSql+j/aopoXMShsuWyDtx0Azxzjr2qzFeCcM0alpB87I3AYDuPevKr46cttj1aWDUOhzOq2MtvJutmJSMgkD7yDvg/0q3pWtbsW12w+ddscoGN3sfepZ2SUl4XLRv8ALknB+n4dKyNTt43UtCmZIx+8jPG/6e9crrKatI7Y0kbdzLsldVACFs4I5DepqFLjMZd2x1I5yc1g6ZqhnC21w53YxFI38X+yx9aupPuMi4JQdsY471k9NwcC+1yJASCFYjDZPP41DbMVnaMtjoV3DJ+v4UkW1uSQzKeAB1GP5UORAd+C6hCVGfyqPaLZE+zZp216sdvsfGV5xnODVyG5EgBdgQOvoB3rmt5jmGVAIAYjHIOORWlYiR8hDuV1zx9K5Z2tc05C9NIys4X5ipxkHAIpsdx99g6lFLD8RUc7lJB5vDEA8d+nB96z1k+fDk7ipPPGPapTTQ3A07u8RNOlkO7A+XaOMdsfrT9NV47ZHBK5+YgcdayL9i2nykqOWGMe1bOjyrJpds5OFKcknODzxSnLkjddx+zvEtvHlUfgjk4POaqplp5WzkFdoXoAKvK+2Rto+Ungn9aSJopmuCVwScIRis1XfUzdLQzHYGRTuKDPb+Q9653xN4J0vxArSrGLS/f5hPCvDf7y9D+hrrHSIgqg2tggZ7981XkkSP5UJzt4yOPrXbRxcotODsc1TDxktT548S+HNQ8PXQh1CIBX5jlQ5Rx7H19utY1fSlzHDf2z295DHPBJncsg4PYYH9a8g8aeCptKeW801Wn037x5y8XsR1x717+Fx0avuz0Z5NfDOnqtjiqKKK9A5QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+jPgN8ApvEFvaeJPFg8jTHxLa2bL81wOoZ/RPbv9Ovnfwa8GQ+INetb7WgF0aCZd6tx57f3QfT1r9B7TZ9lh8tVVNg2qpyAMcAUlUipcvUtwkkpNaM8E8d6FcaZdKJYVSyX5Iig2qnXAHpWJZ2cL3Fq22KaSPJgkPBXI+YZ96+jtVtLa/tXgu4o5I2G0hxmvBvF+hR6LqD/YJWSBiSqnqvNfLZjWlRqckpXue/l9SFaPLazRi6lZbRK2DxlsMvPvj9a564hcAqhKxZ4Yfw/T/Ct03zJCv2qNpo+hZW+YfWla3hMfnRTRmJj1B4Oem4diK876y46M9RU2tzmEQRxOkvDDlQc4Pq3HeoUlEiHPzbc5YckVr3tl+7ZAVecNkZ6fhVGO3dInZGbdnjI6/wD160VdNXG4djmNZtAkn2iMkwyHDY42t2arEM/nwqS2Zjw/Hcf41uTxILdhLGzxyZSTI+4T3/OuVdH0u+Mb4KrznqHX1FdFKr7RW6oPZm7ayYbIGM8YH8Pt9DVpYpmKuqblYkYA4AzzUvhG0TUNSiRmxETzg8g17ppWnabDZxxpbxKEO0g46nvXmYvHqhLltdmM7QWp5Jqnh149OjmAfaV3Lngnvz+FZKSyWxBkyY9pJ7YB/rXtHiX7PHpckexMKCyDpz6fjXit4oleREO0E5P+yKywuKddNSKprnWw65nbJKclegA7Y4FXtJ0eS9tHecsq8Yz2B71kaVu0/VAl8u6NcgM4yPXP+fWuzg1fTrezRR5bnG7g9zyK0r1JU7Rpq/mXKNjz3V47i1doJHUxyN94dD+HatXTJlisLNtm8hT09CareKLy3vXDwgBkcgMvQ1o2yx/ZI1IQKAuF/CumdT93HmQ3DQvxXBIZT2O4Hrj8P6VF5wVN6kgNnI7HB7VEZohtVCRhhgjnHuKy428y3Yl2BWQgY4zz1rKMU9TKRoSX42+XEQFzkNj9M/0pVZmjPyHc+MNis5I+ueqnkZ5//XVk3KrzuPOQRW2i0Rk433HSyEuSuRkYXn+dV/MZxtYDJU8N0P1q3GSE2KRjtjmq1yiopbcd2MnBranUMKlJHlnjnwqLJpNQ05T9nLZkhA/1ee49q4ivd32+S5ZQd2QcjOR/9fNea+M/DZsH+22KH7G5O5ACfKP+HpX0WDxXOuSR4uJw/I+aJyVFFFeicYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXU/DnwpN4v8SQ2KsYrRf3lzNjhEH9T0H/1q5dQWIAGSeAK+n/hPpCeEtAZDGkt3cESXLHGd3ZB7D/GsMRXjQg5M2oUXVlZHrXgjwnp0NtBbWltCllAAqxgf5yc969P021+xWwhViY1PyKf4R6V5z4C1RW1o7QVSRdpRiOD1/OvTjIoXOa8nAVadSUq85WaOnGKcLU+hznirVl0KE3dwf3HTB9a8Q8S+Jm1nUneIFYh03c5/zmvQ/izdXE9k8DKRZggMwAJLHoBXl9rpojjBSQOMenK18rXrUp1ZzW13Y9/LMPCNFTl8TKE7RsJAwKBlIKseR+Nc41y9pcMiMyqemTkAZ6H1FdLrEAjt3Zc+YB0HOfeuReOVRmXBi7f/AF63wzUk2evBaHQWV+lyTBOgjdQRnPT6GrcrYkcuC4kGN46HH8jXKLcbQFOT75PStBdR2RBSwKtxuPT8ff3pVKDTvEUqdtia6uQshVVaQE4K5wSP8cd6ytUhjuY/KTduX5oXP8jWhMFcBhwu3JXuvuPX6VHEPNj8pirgjIPZv/r1dOXJqjHldzL8L6tNol+25VHO1t/RPc+1epP4tNvBFLBkx9W57Y7f5715rqloLtWZFKXkI2gt0ce/vVLR79ihs5ycE4TJ5UjqD/SqxGGp4r97bVbidJM7vxD4vnuJpGtXzHLgsc8dOlR6FPELxZLhY/nUja3X1Nca5WHcOdp4+tJPqk0bhoSFcDIPfgY/lWawUeTkp6Gns1ayOn8ZNbsUlsyPMxt4/iHTPtXMbHHy72QfeLdB61Wh1FnmcSEsBjoa1TcIgLIQCo4Hr9K3hSlQiobidMq28INxGgG7kZA9P84rYaU+Z5ajBXAx1FZmn5TfKcmSToO2M1JJLIwMisd2c+5560TXNIzqLoXTLuCFOGXPJOeQaq20joI1WLcrsxLAj92QMjI9/ao45CsixtksecnntSgEs+0kqGBzj+dFrKxg0S7m8x9xIA4IPWppZVeM7lC47A9qqR4MrAn5Sc/rViRBtypHQcgZGSaHo7GfKaWlospLs2ASCM5x/wDWo1NIwojRV+bO4g54rP8AtMkEYVDy3LY6YqNrg5JYlieMnjPrQoy5uZMhoguSXkGQoUcD04qKTyzC8Mo3ROCHjfkMP8KkYq64bG3JPHGaq3Su2TGGCAjkjH6V30mcdWB5V4n0aTR7/b962ly0L+o9PqKxq9d1TS01ewltp8K2C0bEcq319PWvJ7mB7aeSGZSskbFWB7EV9Dhq3tY2e6PDrUvZvyIqKKK6TEKKKKACiiigAooooAKKKKACiiigAooooAKKKVQWYKoJJ4AHegDtfhboLaprYvX2/Z7FlcgjO5/4QPpjP4V7rCzJKIm+6w+8TxiuX8FaY2i6LaWMqGOdQZJSmAWZuefXHAz7V1UbL5gZwdoHAHSvms0xDnLlWyPosuoezhdrVmha3stndq8Ur4BG7HX612Nr8RvKsJPt258fKpjyCf8AOK4G5OYVKOFfJUA9qqxxP5WRKN/3VB5B78e9fPVEmtXY9V4enU+NGrrvia61ZwJ5ybUuHEZB49zWf/aCRTbsgwkEHHP0qpJHKrEy5Yeo4x9famXFrbGPErtE7nAIbjP1rJwglynZCEIqyLd5q9tJFHHIVj6kk8jBrG1KNLhiYcFl4x0zUGqWjwxqQwlXHy59KpWV9LbExyRM8OOVbn8jW9Kgormps2jG2qGyWL7WKDn88e/9KpxBhKIiNp+n8vWtaK+hcbCWCnOAx6H61BeCGRd8eJJAcEf5+tdUZy2khyY98rGRJzEvIYdAfpSW26Vg6Hfxyg65PpSI5CBgcYHzd/bkelEUSxsGiYpG2SoJ5VvQ1PQz5bl+VwDsnBYlQQTzkVyOu2xhvPtEPI3Z+hFdHuSWIByRIoOVB+8PUf4VSuG3yGGfDBuM46j/ABq8PJ05XEolJ2M0STNghwDwefxqrNtJAU8jg/0NIs/k3720qgJ90E9vQ06SMwsWY8Y79K7EuVlWK8SEXAyPl55q7eMd0cSt1wGAPb1rMkulS7V1BwDzx0rRgkVr1GlGVA7c546VU09JMhtMvGRAQshZlHAxwPwoeUbQFYlDnGaz5Zg0jkjAAI+lV7h3aLapOR0Ge9ZKlc5JzNBNRAl3KQzAdQOo9qspJ5zMV+6xB29/yrlBLKZyFbjBHzDoa1rAyoAW3Et39q0qUFFXRnGVzbRgJGXHPC4x0pskuXxEW8sdfrVK1LCXcx3ZJ+UNiraSpGfmXCrzjFczjZgF5KwiVcEkjqe1Rrl1AZsAd/Sh5fNxIRlj0GenpioZJ1Vkz93sB0q4p2tYznYsqCqBQu7HI9MU1iRnIy3IyeeKprcbTnGRu69/pSvdCWMyEg4PU1rGLuc87WHrMiOMgAkZyRXG/EDTwzRajEp3H93N9ex/pXUOx8xWZTu/nUV9HHdW0ltcHMco2nPY9j+Fehhqns58x52Ip88WjyeirF7bPaXc1vIMPGxU1Xr3U76o8dqwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV1Pw40xdS8TwGXPlWwM5x6j7o/PFctXqPwrthbaZNeEHzJ5Nv1RR6/Un8qxxFT2dNyRvhqftKqieiAl5gjZYspJKsK0YPuASSEDP5cVhJcRxOzORjA2tjOP/AK9acF7BPEPKkX0YKM18hXcmfXU4JJIui4Vdwzv5wM9qhd3O7AKrg4GaqSSJtO4gdfl+nrUMk25Qu0AEdR2FcLjqdcYl7eQQGzg8nPJzUN1KjxGIqOvfvSI+E8wFsgYGe/0qrM7K+CoG3v3FZKN5G0UVgoMqLG5jyeecr+RrYsLC1nik8xgrxjIkDY3/AIdqzJJEcbj3GCD6+oqofPGAqnDcEr0FayjKasnY01ZYkiSKd4U2yqAdyHAP4VDEIo5AYVyTwcjr9RSSKisFc72PBYHnHr71CS4Hrg5+7yfrWqV1uJl28hknxK2Ec5wU9B2rPJVInhkKhwM8fxD29Kme9ddrlSyFdrLnAPr9KrXM6SKsIVgQeGOC30qqcZbMSGi5xNFyQU4VzT7p1uQpK8g5JH86zpSyAeZwQcMw7ex9qdGHXGFUlu2etdHs1uilZsbrFr9qjNyuA6nBVRzj/GmWk8c9tsnYmVeuBjcK0HuASM8bsDrwD71naxbhJfNtcgkbuOOe+K0py5koS+QFa5tlEo3cHnn1FTQJks2DkgAZ9OKg06Rbl3875mVflU96uOSSGY4A42+orSba91mUtivdIFjyowAeueDVPzDk854yKt3U3mpEp+XaTzjsaqLErYdeOhOelaQ21OKqrvQkj4YybQc+3WtGMgwbiRx932rO6KirwTnqacJ2WQqxyOR/9aplHmM0+V6kqT/N8n3wS2Cec5qeORwSzgnu3oTVWEKruOOT19farbFoxhwAB95R3qZJbISTH70lYAEqOxFVpZgv7tiR+FR3TrCMZKge3T2qqd0zq2d2O/tVRh16ESRK/wDpGBkqnqO9Txtzs4IHAHSoj3+XAPvSo4XGASB3HFUYtalmQAOWDFifzHtVWQsSSeASeatwyFSG2j8RSTRiSQyIOM8A+tVCdmZTp32OF8Z2hWaG8Byso2Nn1Xp+lc1XpmtWf23SrmALmTbvjBHIZef5ZFeZ17eDq88LdjxMXS5J37hRRRXWcoUUUUAFFFFABRRRQAUUUUAFFFFACjk17Folq9hpdraocbEG7H97v+Gc15LpsP2jUbaHIHmSqvPua9kR1GBvPA5BHIrz8fK0VE9LLYXm5GhBHK6qG3Yz096HhypAOw/3vbvUQlLRsASw6Y/wpy3BCsWLHAGM189PmvdH1FOyHr50K/6ncoHBQ8Gm/aykm6WNo85wQMgD3xTZL/YoZhxkYUf0qL7RJJ8yRMw5xk9TWXK3q0dsLMkOoADb5zKM8k0wXId8CQMcY4OeajNpJLn7SQEz9wd6dcWVqVOyIqcABlPSi1NaFWJpJyUX0zg8cCljkKtvV2XOcg9MVk+TNFIoilLqezmlM08e7EL8dcH9KfslsmUkbMLIxMzjjeQGxj3x71MpjMKyRt5isPmyPuj0x61z/wBrOCGgIJPHWpV1Er8pDKhxnjuKl0JPYLF6dGZZXiVhEoCnP+elZ5l3YKnIJwGxx9K2xKl7aypNIisVymOFxxnP5VgTLIAq2+CpwzY4HXqadF3umQ1YtohntkmAHoCf4vY1E7KuIkAAOSAP4T3FVJXd59qnaEGNwNMZnRxJvLxHg+x9a3VN9SvIl8wDzFIODyKkDs8SFHJZTtI9P/rUlxF5iB0wHX5wR3Hem3cf7lHQEZ64p6OwSWlzLuEazvN6AKQeB/MVqvIWtw4PDLnOPXrVO7hM1qSWy8f5kUzSXLAxyZwMYz6VtJc8ObqjKXYa+0PgEnnOO9CIfMIJK7W446VYuY/LAYLjJojjBkkY/wB4de1Lm0ucko6jVRWIfIAXjBFNWLezSHPynbnpzVp1AdSODkt0qSyhQ8fN82WOfWoc7K4eyuVrdA0RkbJJbJNE5IG7sBx7e9W3AigWJSMD7xB6nPSoTGLglFBVieSOlJSu7sXJ0Mu43ynngAVcsIG8sZ27OoqzBaqHIXAx2PXFalpAhgDqCvJxkdQKKlZJWRPszHZASRtwO1MFuQ4OQegGO9bNwYwd+N2ONv8AUVRSMuvJKLnqamNS6M3SuKsJMYJPOeBmnmEDhV+cdqkhkQSeXH8x9egpL2QQIwXbLNniMvtH5jNCk72IlAhOMqdp6jIrybVrb7Hqd1b9o5CBx2zx+leryvcOGESBV+lefeOLV7fWFkfOZ41fn16f0r1sunabi+qPJzKn7il2Odooor2TxQooooAKKKKACiiigAooooAKKKKANTwyu7XbLgHEm7GfTmvU/MXaFYPux26/jXmXhGJZdchDgFVVm59ga9OgdAzJy5HXAyRXlZg/eR7OVq6Zcsmi8oBsgn7ox0pwKls70XqTyOlQb5WGLePYo4Dvgmny2TSqA8rYPJwO3t6V4k7X1Z9FTiMhHnSmRV3BDhT/AFq7HE+7lCAOhxS2disaFFMhIGRhhyPepkgIXKyd+FNc9Sor2R1RQyb7gQcMBnPqapSh1JIBO48AVplHYkGBmI9Bk/nUbxSBgQETj+Os4zsbJGQ5ZCctxnGQP0prn5eR15x6VcktyCXaRdhwMDrmpEjWeUDGGOR0yB/9atudbhYzvMUEAxsU35Kj09Kjuo8ukcSvljlQ3Ug9K0Ps0jTKJFII6EdDTryCbaCIZCUXGcEcCqVRJqw2jIuFltpirEhhwykcVI0zjcqhQW/iHOK1PKi+z/vUMrMMkkck471X8vY/7mP5VHOeopqonugehkEFWCAZyepq3HA235gAG4I9amht8JuQZYnkdTUtvGd4fJOcZBHStJVLkJa3Y3TbcsXizlQCV9xUz2YETxkcryAeuKtLG8EyzdUHBBHGPStm4gDyQyJh9wwxHcEda46ldqV+5ocuNP3WzNtBbOAce1ZemxmO52YOTlevpXctHHb2xgVDJg8j0FcvHG8l2z7QGDMcD/CtqGIc4yT2EldCXsYYnbHgAZHtUtraZaRcKVCggg4+b3rUFisrfMWA2gE9TWrbaI73CNECVxuIzwQO54rGeKjGNmzFxS1OUkgOJXBACHA5qS0RYLczyDLMMqp9Ku6nBtneGJeCSOP61SdiSowcAfdrSM+eJPL1GC3iKDeoCt820E8fjTRGoYqgB7Zz3qaZ2BKQAHI5fHb0FVokfn+6P4j1q021dsTiSo0cTn5sZGWA/wAauNexphI0JXHOeQOKrwRBl5HAwc4oEDO4UL8mcrxxUSUXuRJEiOojRBjPOT+NQSKFdtxwvIxnpVq4ktbeLKsC/wDFjrmsoSfaJtxHHWqppvXoQ0PggkuJfLtxhTxk9a6XSfC811giMEj+Ju34VL4W0qK+uUQOVUdecGvRkNrpUHlxPtLD7zc8+hrgxeOlCXs6e5nNqOx5xrmivYxg4ZmA5GwgD8fWvJfiLENlhMOT86bs544I/rXsXie9mnuW+Y7CeMdD/hXlvxHjYaVCzptIn/mpr2cpnLnjzbnlZhDmots86ooor6s+bCiiigAooooAKKKKACiiigAooooA2/CK7tZXn5gjFRjqcV6Vp+yJtsh28c45NebeDRnxBbj1Vx/46a9Nt0CklfTHSvIzFrms+x7WV3s7dzQgMZf+LoMDpzVllcklR8n49feqURbaFUkDOTnvU8Ep4C55zyTXg1N9D6SnsXPm8/JGdo5Kg8VaiZV2gqwGDn61DZrjcqs4yMk9c1cRQjlmBLdiTzXDUktjoRETIgYxPwfvEjBAPYVQuVOWJbJPGCOTWtKBJ91QDjjJJ7+tZ88Sk7gwxj8j6UqclctMotAzIqiL5j1OOvpU1tEhkO2PY6jBye3erR643kHgc/SnBApbcFOAOgx+Oa0dR2sUmT6eXM6C3Vgcn3P0x6V32mWqXtm63EDCTb8uRkdPSuY8KeRG5bKhg2CMV6bYzQrbiT5XXGc59q8HMq7i7RRy4io47HkOvaFPZuxRNrNk7Seo7AVzUSEOwZdjk46f1r1TxeYr6R3EigKMDacGuEe0PmDzMMdxO4dT+FepgsVKdP39zenNyV2Zf2bfIBGfnHUCtO2tUDvuUkEcEjvVi30/fl1I47NxVi1ikjdSwA3A98g1rUrXVkyghs0MgViAjjGQOc+tWbC1ZYzE52ujkZ9atwQlSFY4KDIJ647CmXJD3qFWCs6/Me2RXG6jloF76Gdq1n5coZcg7d3txWNpNoZZzKACE5Oeckmuk8RXI+xr5YzJkI3J4BHJqOwgit7ZFKASSNuyeuPStqdaUaWvUpO0QhtVt7ZSFO5ju5/z0q3JdSLZtHbqUcDkjjI+tTQIHLPIAsaDHTnn+dQ308QizFHnvnoQK5ubnlqrmT1ZzrWwlildDl2Hfr9ayxaiIKSVYAkHvzWon7i7Zy+YwMgVnajIjcA7MHJI4/8A116lNyvboOXkUpW2eYqkYPrVOCdMlHO7nJwM9KrXH2i8mEduG2en+NalnpGyMbmYtnHH8q7mo04+89TP1ITqJQkRLub/AD2pqxX904GHUMeADitmz0+GNSZMDJ6mteIRgqiKQx4xtIxj3xiueeIjD4ELQxdP8NPJgyZdu61pSaGbV9jQhQ3PNaNheGwnLyE5YYxio7/UHuZAx49j/PNccq9ec/IlydynBLc2DKyKjDPT7p/OprzVpp0+SJm54yOlRwgyB/M25GcYPb1waJfmGCdo9vSqSjzXa1M56mJfSXEiFwCvbjnFcP4/80aWnmPuHnLx6fKa727PUAArnOf5VwXxCmDaZbx5BzOTnvwMf1r3Mv1qxsjx8wdqTOAooor6g+aCiiigAooooAKKKKACiiigAooooA2PCUvleIrFgPvPs/76BH9a9XtQWG9E3DkAH2rxexmNveQTL1jkVx+Br22B1jk5ZinqBz7V5GaR2kezlUtWi9CjnyyMLIO2P196kdDFKEZ1+UA4AqKNixDljwCcdD+FWwqsd4A2EjaSeh96+bm7H00SzEwSP5RsGMAen41MQpIHyg4IJxz+NVV8yGbht+c8DoD656/hVh2UwbvMDTFsFNv3R657muSa1NkKQMfLgKp27S3WoGiVvmC8k5AJpEcNuWUlSOVGOv41KvHZRg5FTrEpMhuYhuUg/L3PpRKE8lNod5SMNn7vtVicnywSVLnr7ClhQrtyCQMd8UKWhSYmlvLa3aShA3qOldl4ae/1F5LZVOx8FnUcAf41hI8Ujru3ZxwR0+leveALCOHTEkQhmcc7fX0ry8fW91Wj7z0Rx4yuqVNza1Oa1TwU3kM+55MjJBNcf/ZcdpNPHduyup+XcONvof8AGvoGeNQOR1rivEttb7JMqCT6jPHpXCsTWw0/ZVXc4MHmEqr5ZHjdxIbXJZh5T9Ux2rWsEF0CGxwBt57dqg1KyzPIYn4zuG4cfl2os7YKmR1btnPOf/rmvXnKMoXT1Pa0aLkixxI0YJLZ28/41UljdoxsXa0RLqW9B1q7EkkZBbDhh8wcdxUt1LbixupJSInVfkQNy5rFSaatqCdmY88q3DKGQEgAjHQ1LGpKhhzIoO09cmqmmwvf23nQny3RyvznIx2+lXigjt3LqVuchNo6EnvW8rR91Gj00J2mHkiNMrgcjqM1lsisJM5QnkVovbkEhCNw4HHeqlyqRFvMbGRnB9T1qabS2JRh3iiR2YA9MsBWBqDNI0cMZzk4INbt9I0gWKHc2eB2H41DZadsfzJ+D2FerSmqa5pDasrsh0y0CRBVDGXPO0f1rVWKUkYjKjvirClYJcwBVIX5QT6VW1Nr6OPIhLSMR5YDYByepPoOtYOo6kvU55X3II7farbhvcZyDzitDfGtsjrJtcLgg9qy/KdWYNJjd3pZJ4Y+NzZ75PenKPMK1xk8srOTnjd27inRKzBQNxPYdOtU/tUW5SsmQD0zVz7fGId0TFmHG08c1rKLSskPlZoxWr8NxkDHUflVK/3RFgYtuPQ5/lW5pKHUoArL5L7flzyCaoa1HNYqqyKrL0LIev8AjXPSnepyvcyn2OSvZ97sUjOPyNcH8QJT/ocZBHLvyfoBXoVzuZi6lPWvNfiFdLNrSQoMCCIKf948n+Yr6bLI3qqy2PCzOVqT8zlqKKK+iPngooooAKKKKACiiigAooooAKKKKACvYPCMyXOhWUsgEjBNhG7BGDj+grx+vQvhnfbrW70/YvmKwmVz6Hgj+VcGY03OlddDvy6pyVvU9Dt4CdhOAp5GWq5FHuUgFVGDuyRxVOAgeW8Zww5Hck+gqW1MMkoUy7FBKttHRgOB+or5OqmfW05E0kqRovloXcc7ientilg3YMjjKp0BPU0lpGkxOzaW5yWPBq7HEVeSNyFKYGc8HFc02o6HQhokYxbVVeRj1xTRmFyrIHjP3QOqn3qREMrHEm1TzkipDHFywG/5cc9CawbSK2K73MSBmkKbuqAnAHt7+lSeaZJDKT8u7PSoPLiYorqOTyBzVhLeJCgxxjPPem+VD0JY50jlAGeDxxxXuXgeBrfTYd4O5+cYPHf8K8MmVGyignvxxivUPBHiBrizggebEgAXluRgdq8vME0oVEtE7s4MxpyqUrRPRL64EUe4kY6V5L411otdNHC4wueVrf8AHWrG308Is3zuex7V5HqNzJKxYMeDg4HT/wCtWOFpyxlX6xU26HPl2E5FzsmW4leQ7W+YqdpJxz2NbVtEGUMrESdCx6/WuXhLgcnnPXNTNqFxZ3FphX+yyvtmk5OzsPpXqVKLlpE9lRvsdXmR9oZlwQc5Xj8KwvFSRxaWVt0Dzbhu281twxknKtuycnnP0qzFZwrkvHu9SecVxQqqlJS7EqSi7mFHZTabZW11bJuikiRZ4vf+8KfrFnNDNZXMnEZkCEYIz3GfXrXTebHbLDJIFWP7nPHPY1FLdR6nrcNnHghFLbzyFNSsTNy5mtNbvyF7R3vYwr2wv47mSPzwkY5XC8kVGtrBbx5mUytjJLHrXR3Eu/zIJgglTo6/8tAPesi4JWTAG5eucZqqdaUlZjjNswdThAUMibWIwNvANZ7xytGckjHHJ/lWxqrIU2eb6fL6GsqOXB+fmvRpNuI29CfRWCTFZUVkA/i6ipNWluZiDHESoGBn0psECFhJ0HOGPUCiW/ZYo4wTIgJ+XvQ1efMkZvczHsrgoTIzKfTPasG8tXRzlmJ6DPGa62O9jZCrEYz6859Ky7y2jZldmJx0I7V10asov3hKWpyu2SCTbMnHb1rb0m2V0d1T5wMhc5BqLULbpwRgcVZ0knb99gw7Y6111anNC6L5rGt/ajxxLGgkjaMYyBxmsTVLm4uG3TOxGcZxWnctlvnYgnuO3v8ASsq+lQElueQARWOHgk7pHLVkrGbO8iqAzHA7nv8ASvKdYuTeapdTk5DyHB9ug/SvRPEF79l065mR2BVSq56licCvLq+nyynZOZ8vmVS8lEKKKK9U8sKKKKACiiigAooooAKKKKACiiigArV8M6h/Zms29wxIjzsf/dP+HX8KyqKmUVJOL6lRk4tSXQ+iNPvLY2UkUlsHupOVl3YAHrVxLacRLI0ZETHZk4ALfWuP8AXkWp+HEYyMb21IikBAOR/C35cfga7BHbJg8xjH1Qnnmvi8VSdKo4n2eEqqpBSXUsWIh3fPHujyQzA8jPf2wakSBon2rghRghj696kks4FC7LnfIy7244H/ANepGhlcNJvQlTnk8mvMnJXumd0WOCvG8quiHzU6nnH0PY1UZWQkfe+lXlibKAsDnnb6e4qX7FtmkEpG5f4T3rn51HcpMyoYnj2HghWBApJOZ2Ow7WOFUdRWg0X3dvGT16VF5QLBfmDAk+7etWp31GULpZCC2VbkEYJ/WpNOu7jT5BLEw3Rnt0P/ANapJI2YBjkqGOMdvekSDa2zrnnGOtXdONmPyZbv9TlvQDKWO7BHciq5QzQkRBTs+8QOopuCpERXD+npVxXMOAgG4dVPesrKCtFC0WxBZ2zO67gB6Z71v21jujdCB5RXkHvVKN1JZGWMxnkMOorZsUdIcZAjA655b2rlxFSW5LkxbaARxhFJCDIx14okkdsJHkuTgHqBWjFGpJUk46lVqSKLIztACDk464rgdXW7I5+5z/iGApY2pll8yQknaf0NTaOi2acbWmcbnJ7e1TMRcXLvPtBJKqM9BWZaTBLtrS4BEin5GH8XPSuiN5U+TsaLWPKaVyoZkdRgA5I6YPc1WuXKByirkAE81YWQHAYZAzlT1+tZ+qS5Y7CN3Q4GMiinFtpCXY57V5VnZsKNo6c1hspDsqOw54U1Yv5THL5ZPzHkZ9aqKHfLMuO4I6171KHLEt6Fq1kkklUEhWxsL98ZqxIqxtuVSJRgHHT86qW8TbwcnB7rV8wuq7iCSOuOuKU2kxblG5jhmlVmTYQOcE1GybCRH82eCCeoqS4R/MVom75IIxirccBeMH5iWHXpVc3KkTYy3Jf5fKYA8HJ6UQFIyFVipxkA8D860HhCjcckc5FZd00eNrZOegNawfPojOTsiw3O4sWK4Hy54FYd9KTKcNx0we9PkndFKq2U6YPJBrIv7grG80h2ooLN+VdtCk7nBiKqUTl/HF6xeGzVhtA8xgPU9K5SrF/cveXctxL95znHoOwqvX1dCn7OCifJ1qntJuQUUUVqZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAG94M1kaLrcU0pzayfu5l/2T3/DrXuTxLmNosZIBGDzXzfXq/wAPPFi3VrBpt9j7XageRIf+WiDnafcfy+leNmuFc0qsOm57GVYrkl7KXXY9GS3kbOMKw7t+Vao05FtVcSM0rDkDjFU9Lvre6MskjhwxJYD+E1r2e2Vtikqp/iI4Jr4zEynF2elj6lN2KosnMCzRSB5T1QjHTpz3qXbxtJkVlGCDyc960ym1yAQQM845pk8G4fMS3PUHB59a4HVb3KUjN2x+YCzfLnJUmomj3NwgwDgH0Fax05Y1yRvOODjFVZbUttQOzMMjPA4HanGqnsx3RAYmYYVQeecdsVBLblpMt1BwMd61YkYocKEYdRimSNAiHeRuzgjOTQqjT0FczGhBDMcDbypB61HBG80m8rhwcA/0rSmLyRBkRVXoM96SMRRhXLEPj5Qo5rRVHYLk8Fsgtw/l7WONwx1q1BKqg9TjoKqxF5X7ovGc9/anvCzShXyRnPHpXNJX+JkmtDcrkYUKOhJ5q3DJ/o8r8Akcc8D8KylhZ0Rl2hc5wM8iroy3mLECFxjGM4+tck4roQ0ioQFijDAAEfLmsvV0UxpOM+ZHjJHH41q3IbyAxJ3opGMVkXj484Mcl4/wrpo/Fc1g9RTcZO/d1G8YPt2qjeSAkMhypBOPenWA32is4UqOQT6ZqGeRTAQpwASQB611xglKxT0Zm6jbpOdwVsEYbjoawT5ltcFD0zlWPQ1vvKySDcp2njjvVa7hF3Eywgbh8y5FejSm46S2HuV7aZVc+aME849D61rI+RlW5OMYHIrDsmW5by3IWdMAE9x6Vc3vbMxcHPHA9fanUhd26g10LMlv+8LYBx14/WnqzoU2nBxkHsf/AK1Ngn8xMxIWJI3D0NOkR0ysigZ7jv6VlrsyXoQXgbYflwGPboT9a57UlAd13Kx6jFdPK6CEiNwzDqG7VyupKzljjAGfqPauzCbnJWloYly+0scn0x6VyXizUCY1tFY7id0g9B2H9fyrZ1i+FjA0jgEjO1T/ABNXAzSNNK0khy7HJNfT4HD3fO9kfN47EfYXUjooor1jygooooAKKKKACiiigAooooAKKKKACiiigAooooAKmtZ5LW4jngcpLGdysOxqGihq+jGm07o+jPholtr+jpf6c5E6nbcxddj9enoexr0O1tFL7ZsrjAJXqv1r5O8GeKL/AMJ61FqGnSHggSxE/LKndT/jX1l4U1qz8Q6NFqmmS+bBOdrAjBiburD1Hb1r4LPsDVoT9otYPby8v8j6rA4/6xDll8SLcNvGWZVDAKTtLHqO31pyWwQ5CkrwcHira24SNegUNjjqDjpViOP5TuywGMdu9fKTm0ehzFBbUlTvA2g5PJ5qvLCiEsFHHQe1bNyxBOWCr1NUZBvjKQglifxrOMn1BSMW9XG4fMTgbj6moraxIYPLjb15rb+ylpQG4A5LHv8AjTzbhBgANxxnoK2Vaysi+fSxUNsqRqyg7u1V0tRlWVQS2Rn0rYVDImNwDH5cGmT2bBSxJO0cgd6lVOjZPMZkduFUmMEnqx9aUhTFlccfKeetLdu0a9BkcgZxWWbkAMxbKk/n7VvGDkrlJNmsZdseyMZY8rx1q3aYh/1mG4+73J/+tWRZ5Tc7jluv9K0YvnJBHzA5waxqQtoDVtB8/ltkhSw9B6/4VzOvsiQyNgErjafStvUp/JJXuV59K4zWZXeMIVB3Z2kd/rXXgqTcky6S1LmjTf8AEtaNwQxOQMetVXB2uEBzzUlsyRQxhieF/lS3QVVYpkJycV22tNtdS5PVlGCQOCGwGYHPHJxTYSEwSxwe/of8DSQwkbSOXT0NWIzsbaVyrDoa6H5EqVmYmuQmF1u7cFXz8wXsa1NFePWvLS7YA42lgcEVIACjRnlegJP86r21jJZ3yXFqG27vmXup9quU1KnyvRrZmjlodhP4EuLeBbqwnLHqAfT0rGumPlSC4iEbJ8rL3/CvZfC90t5o6N5gOFAcHkrxxXD+NfD6TyStCwSYngjp+dePQxM3JKs/mcNHEe0m6dToeX3txGJF2sP9nHQfWsK7uWiZy5GzGWycBR65p3iVZLC9O4FXAw+eh96868VeITfqLS1Y/Zl+8x6ufb2r7HBYN1bcuxxY/ELD3T3M7xFqf9o3x8ri2jJEY9fc/WsmiivqYQUIqMdkfLTk5tyYUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXUeAvGWo+DtVW5sj5ts5AntmOElX+h965eis6tKFWDhNXTKhOVOSlF2Z9oeDvF+m+KtIF/pj7iPllt3xvhP+0P0B71uJcsNx4x2z0x6V8VeGfEOpeGtTS+0m4aKUcMvVZB/dYdxX0/8M/H2j+MIUi3x2WqAfPZOw+c45KE9R7da+AznIZYa9Wkrw/L1/wAz6TB4+NZcs9Jfmd6sIdgUGcrnOc1ZNoYkXJPH+etQwTpHII4gSw46YxWzBEHGZTkgY55Br5WdOS0OypUcdTJaAuvyk8HIJ6moEi8yRtqnAHT1/GtqeHIABKoOpz296o3BW1idmdURB8zHoAP6e9Qou441OYqxW7CUtkFj0Pv6VbELiM5UFscBj1rPiuBdMnl/Mi/MrL/F6EetaUcE8hV5N2GPUDJpuL6lT03ON12NhdeQq7y2dzGqa6e+7cU2IuDtx7969AOlxjdI/Lsec/yqhf2wWMxwo3zZHXpXVDENJRSNYYhNcqMAW8gRiwAOefxquJGW6K7du44GeMitdklEoQjMfl9Rxg+prJuEbzGDMTMR8oxwcVUXd2LTuVr4/aJMthUU4BPWubZhd3WEICq2cdK0dZuTBaqm/wCZj83PpVTSbUqvmOoy3JDcYr0aMeSHM/kbQ0VyeS124xnkcAjoB/So7jmLaPTrirxk37gOAowMD61RnAB2kDr0A9qcLt6kXM2KQrKRIc456dqmnDMqlSpwMjFQXKbnVlBUDrg4okkVI1y2AOTxXXa9mhNpDLibyzvYEA9cVZg1NrSNZNnmbGwc96xr27ALZYNnjBPSs9rnIKMcgn1610LD88feM3VR6zpnjmxt7YRo+3zeozxn+lS3/iq3bTHMkiFIxuLkjgepPoK8J1PUYLOFnu5TGh4Bz94+gHf8K4bW/FmoahA1pDNJBYkYMaty4/2j/TpXRQyGNa3LseRicZTo69Tofin40tdfuvs+lR4iH+tn6GQ+gHp79687oor6/DYeGGpqnT2R4FatOvLnmFFFFbmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFPikeKRZInZJEO5WU4IPqDRRQB9E/Az4naprGpQ+H9ZhW7criO9L7ZFA7MMfN9eK+gbV3S5WNmLF1ZgfTbt/nmiivzzP8NSo4q1ONrq/wAz6HDVJToJyd2aESLheuWAqrquiwBNzsX3AAgjt6fSiivnEk4N9gVSUaiUWR2djAmQigBDwMdPpWwIkjjGBwRkD0ooqoQilJ21FWnJy1ZDeRLkjsQKwLld+MHaR3696KKcornt/XQ3wrdirdIqrMSM8fT1rKnhHllyckISP50UVlFWdkd8GzgtTAl1XBHBG4e1bEWEjK4yMZ5/OiivXqL3YryOyWyGO2wbscHjA4rJu5Qdx288Z5oop0EuYyZiy3THL7RjOcdqgublzujPIOQSfTrRRXrU4rQwm2c9cTlnII+XHrz+dY/iTU202xWWOMO5bau48DjOT6/SiivVwsIyqRi1oeXiako05NM8+1G/udRuDPeSmSTGBngAegHaqtFFfSJKKsj55tt3YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Narrowed arterioles, exudates, and hemorrhages in grade III hypertensive retinopathy in a 54 year old black woman with hypertension and azotemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Eli Friedman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_51_26431=[""].join("\n");
var outline_f25_51_26431=null;
